ANI Pharmaceuticals (ANIP) 10-Q8 Nov 232023 Q3 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Nov. 01, 2023
Document Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-31812
Entity Registrant Name	ANI PHARMACEUTICALS, INC
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-2301143
Entity Address, Address Line One	210 Main Street West
Entity Address, City or Town	Baudette
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	56623
City Area Code	218
Local Phone Number	634-3500
Title of 12(b) Security	Common Stock
Trading Symbol	ANIP
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001023024
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock
Document Information
Entity Common Stock, Shares Outstanding		20,426,683
Class C Special Stock
Document Information
Entity Common Stock, Shares Outstanding		10,864

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 193,078	$ 48,228
Current restricted cash	0	5,006
Accounts receivable, net of $97,774 and $161,052 of adjustments for chargebacks and other allowances at September 30, 2023 and December 31, 2022, respectively	178,842	165,438
Inventories	106,590	105,355
Prepaid income taxes	0	3,827
Assets held for sale	8,020	8,020
Prepaid expenses and other current assets	10,690	8,387
Total Current Assets	497,220	344,261
Non-current Assets
Property and equipment, net	44,189	43,246
Deferred tax assets, net of deferred tax liabilities and valuation allowance	84,389	81,363
Intangible assets, net	219,828	251,635
Goodwill	28,221	28,221
Derivatives and other non-current assets	16,067	11,361
Total Assets	889,914	760,087
Current Liabilities
Income taxes payable	594	0
Current debt, net of deferred financing costs	850	850
Accounts payable	34,077	29,305
Accrued royalties	11,975	9,307
Accrued compensation and related expenses	15,328	10,312
Accrued government rebates	10,923	10,872
Returned goods reserve	31,438	33,399
Current contingent consideration	23,939	0
Accrued expenses and other	5,228	5,394
Total Current Liabilities	134,352	99,439
Non-current Liabilities
Non-current debt, net of deferred financing costs and current component	285,032	285,669
Non-current contingent consideration	10,560	35,058
Other non-current liabilities	5,259	1,381
Total Liabilities	435,203	421,547
Commitments and Contingencies (Note 12)
Mezzanine Equity
Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at September 30, 2023 and December 31, 2022	24,850	24,850
Stockholders’ Equity
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 20,653,794 shares issued and 20,394,244 outstanding at September 30, 2023; 17,643,497 shares issued and 17,494,466 shares outstanding at December 31, 2022	2	1
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	0	0
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	0	0
Treasury stock, 259,550 shares of common stock, at cost, at September 30, 2023 and 149,031 shares of common stock, at cost, at December 31, 2022	(9,850)	(5,094)
Additional paid-in capital	506,513	403,901
Accumulated deficit	(80,880)	(97,286)
Accumulated other comprehensive income, net of tax	14,076	12,168
Total Stockholders’ Equity	429,861	313,690
Total Liabilities, Mezzanine Equity, and Stockholders’ Equity	$ 889,914	$ 760,087

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Adjustments for chargebacks and other allowances	$ 97,774	$ 161,052
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	1,666,667	1,666,667
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Treasury stock, shares at cost	259,550	149,031
Convertible Preferred Stock
Convertible Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible Preferred Stock, shares authorized	1,666,667	1,666,667
Convertible Preferred Stock, shares issued	25,000	25,000
Convertible Preferred Stock, shares outstanding	25,000	25,000
Common Stock
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	33,333,334	33,333,334
Common Stock, shares issued	20,653,794	17,643,497
Common Stock, shares outstanding	20,394,244	17,494,466
Class C Special Stock
Common Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common Stock, shares authorized	781,281	781,281
Common Stock, shares issued	10,864	10,864
Common Stock, shares outstanding	10,864	10,864

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Net Revenues	$ 131,829	$ 83,821	$ 355,162	$ 222,153
Operating Expenses
Cost of sales (excluding depreciation and amortization)	48,101	32,894	128,093	102,459
Research and development	11,121	7,657	24,419	17,096
Selling, general, and administrative	42,007	30,081	117,235	90,856
Depreciation and amortization	15,207	14,167	44,597	42,488
Contingent consideration fair value adjustment	(2,555)	2,476	(559)	2,134
Restructuring activities	0	1,541	1,132	4,111
Intangible asset impairment charge	0	0	0	112
Total Operating Expenses	113,881	88,816	314,917	259,256
Operating Income (Loss)	17,948	(4,995)	40,245	(37,103)
Other Expense, net
Interest expense, net	(6,398)	(7,264)	(21,194)	(20,546)
Other (expense) income, net	(39)	37	(126)	712
Income (Loss) Before Income Tax (Expense) Benefit	11,511	(12,222)	18,925	(56,937)
Income tax (expense) benefit	(1,571)	3,622	(1,301)	13,284
Net Income (Loss)	9,940	(8,600)	17,624	(43,653)
Dividends on Series A Convertible Preferred Stock	(406)	(406)	(1,219)	(1,218)
Net Income (Loss) Available to Common Shareholders	$ 9,534	$ (9,006)	$ 16,405	$ (44,871)
Basic and Diluted Income (Loss) Per Share:
Basic Income (Loss) Per Share (in dollars per share)	$ 0.46	$ (0.55)	$ 0.84	$ (2.76)
Diluted Income (Loss) Per Share (in dollars per share)	$ 0.45	$ (0.55)	$ 0.83	$ (2.76)
Basic Weighted-Average Shares Outstanding (in shares)	18,883	16,303	17,663	16,238
Diluted Weighted-Average Shares Outstanding (in shares)	19,125	16,303	17,823	16,238

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net Income (Loss)	$ 9,940	$ (8,600)	$ 17,624	$ (43,653)
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustment	(38)	0	52	0
Gain on interest rate swap	388	4,609	1,857	13,094
Total other comprehensive income, net of tax	350	4,609	1,909	13,094
Total comprehensive income (loss), net of tax	$ 10,290	$ (3,991)	$ 19,533	$ (30,559)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Accumulated Other Comprehensive (Loss) Gain, Net of Tax	Accumulated Deficit	Convertible Preferred Stock
Balance at Dec. 31, 2021							$ 24,850
Balance (in shares) at Dec. 31, 2021							25,000
Balance at Sep. 30, 2022							$ 24,850
Balance (in shares) at Sep. 30, 2022							25,000
Balance at Dec. 31, 2021		$ 1	$ 387,844	$ (3,135)	$ (3,055)	$ (47,765)
Beginning Balance, Common (in shares) at Dec. 31, 2021		16,913,000
Beginning Balance, Treasury (in shares) at Dec. 31, 2021				83,000
Beginning balance, permanent and temporary equity at Dec. 31, 2021	$ 358,740
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	10,862		10,862
Treasury Stock Purchases for Restricted Stock Vests (in shares)				63,000
Treasury Stock Purchases for Restricted Stock Vests	(1,840)			$ (1,840)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		24,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	690		690
Issuance of Restricted Stock Awards (in shares)		723,000
Restricted Stock Awards Forfeitures (in shares)		(46,000)
Dividends on Series A Convertible Preferred Stock	(1,218)					(1,218)
Other Comprehensive Income	13,094				13,094
Net Income (Loss)	(43,653)					(43,653)
Balance at Sep. 30, 2022		$ 1	399,396	$ (4,975)	10,039	(92,636)
Ending Balance, Common (in shares) at Sep. 30, 2022		17,614,000
Ending Balance, Treasury (in shares) at Sep. 30, 2022				146,000
Ending balance, permanent and temporary equity at Sep. 30, 2022	336,675
Balance at Jun. 30, 2022							$ 24,850
Balance (in shares) at Jun. 30, 2022							25,000
Balance at Sep. 30, 2022							$ 24,850
Balance (in shares) at Sep. 30, 2022							25,000
Balance at Jun. 30, 2022		$ 1	395,043	$ (4,736)	5,430	(83,630)
Beginning Balance, Common (in shares) at Jun. 30, 2022		17,566,000
Beginning Balance, Treasury (in shares) at Jun. 30, 2022				139,000
Beginning balance, permanent and temporary equity at Jun. 30, 2022	336,958
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	3,870		3,870
Treasury Stock Purchases for Restricted Stock Vests (in shares)				7,000
Treasury Stock Purchases for Restricted Stock Vests	(239)			$ (239)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		16,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	483		483
Issuance of Restricted Stock Awards (in shares)		54,000
Restricted Stock Awards Forfeitures (in shares)		(22,000)
Dividends on Series A Convertible Preferred Stock	(406)					(406)
Other Comprehensive Income	4,609				4,609
Net Income (Loss)	(8,600)					(8,600)
Balance at Sep. 30, 2022		$ 1	399,396	$ (4,975)	10,039	(92,636)
Ending Balance, Common (in shares) at Sep. 30, 2022		17,614,000
Ending Balance, Treasury (in shares) at Sep. 30, 2022				146,000
Ending balance, permanent and temporary equity at Sep. 30, 2022	336,675
Balance at Dec. 31, 2022	24,850						$ 24,850
Balance (in shares) at Dec. 31, 2022							25,000
Balance at Sep. 30, 2023	24,850						$ 24,850
Balance (in shares) at Sep. 30, 2023							25,000
Balance at Dec. 31, 2022	$ 313,690	$ 1	403,900	$ (5,094)	12,167	(97,285)
Beginning Balance, Common (in shares) at Dec. 31, 2022		17,644,000
Beginning Balance, Treasury (in shares) at Dec. 31, 2022	149,031			149,000
Beginning balance, permanent and temporary equity at Dec. 31, 2022	$ 338,539
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	15,031		15,031
Treasury Stock Purchases for Restricted Stock Vests (in shares)				111,000
Treasury Stock Purchases for Restricted Stock Vests	(4,756)			$ (4,756)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		170,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	7,027		$ 7,027
Issuance of Restricted Stock Awards (in shares)		648,000
Issuance of Performance Stock Units (in shares)		85,000
Restricted Stock Awards Forfeitures (in shares)		(77,000)
Issuance of Common Stock in Public Offering	80,556	$ 1
Issuance of Common Stock in Public Offering (in shares)		2,184,000	80,555,000
Dividends on Series A Convertible Preferred Stock	(1,219)					(1,219)
Other Comprehensive Income	1,909				1,909
Net Income (Loss)	17,624					17,624
Balance at Sep. 30, 2023	$ 429,861	$ 2	$ 506,513	$ (9,850)	14,076	(80,880)
Ending Balance, Common (in shares) at Sep. 30, 2023		20,654,000
Ending Balance, Treasury (in shares) at Sep. 30, 2023	259,550			260,000
Ending balance, permanent and temporary equity at Sep. 30, 2023	$ 454,711
Balance at Jun. 30, 2023							$ 24,850
Balance (in shares) at Jun. 30, 2023							25,000
Balance at Sep. 30, 2023	24,850						$ 24,850
Balance (in shares) at Sep. 30, 2023							25,000
Balance at Jun. 30, 2023		$ 2	495,488	$ (9,180)	13,726	(90,414)
Beginning Balance, Common (in shares) at Jun. 30, 2023		20,536,000
Beginning Balance, Treasury (in shares) at Jun. 30, 2023				248,000
Beginning balance, permanent and temporary equity at Jun. 30, 2023	434,472
Increase (decrease) in Stockholders' Equity
Stock-based Compensation Expense	5,444		5,444
Treasury Stock Purchases for Restricted Stock Vests (in shares)				12,000
Treasury Stock Purchases for Restricted Stock Vests	(670)			$ (670)
Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)		125,000
Issuance of Common Shares upon Stock Option and ESPP Exercise	5,581		5,581
Issuance of Restricted Stock Awards (in shares)		24,000
Restricted Stock Awards Forfeitures (in shares)		(31,000)
Dividends on Series A Convertible Preferred Stock	(406)					(406)
Other Comprehensive Income	350				350
Net Income (Loss)	9,940					9,940
Balance at Sep. 30, 2023	$ 429,861	$ 2	$ 506,513	$ (9,850)	$ 14,076	$ (80,880)
Ending Balance, Common (in shares) at Sep. 30, 2023		20,654,000
Ending Balance, Treasury (in shares) at Sep. 30, 2023	259,550			260,000
Ending balance, permanent and temporary equity at Sep. 30, 2023	$ 454,711

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash Flows From Operating Activities
Net income (loss)	$ 17,624	$ (43,653)
Adjustments to reconcile net income (loss) to net cash and cash equivalents (used in) provided by operating activities:
Stock-based compensation	15,031	10,862
Deferred taxes	(3,394)	(13,628)
Depreciation and amortization	44,597	44,081
Acquired in-process research and development ("IPR&D")	0	1,151
Non-cash operating lease expense	888	0
Non-cash interest	2,970	2,963
Contingent consideration fair value adjustment	(559)	2,134
Asset impairment charges	0	574
Gain on sale of ANDAs	0	(750)
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable, net	(13,404)	(11,907)
Inventories	(1,236)	(14,164)
Prepaid expenses and other current assets	(636)	2,617
Accounts payable	4,772	(5,027)
Accrued royalties	(2,668)	360
Current income taxes payable, net	4,426	(111)
Accrued government rebates	(51)	3,253
Returned goods reserve	(1,961)	(1,818)
Accrued expenses, accrued compensation, and other	7,820	(3,740)
Net Cash and Cash Equivalents Provided by (Used in) Operating Activities	74,219	(26,803)
Cash Flows From Investing Activities
Acquisition of Novitium Pharma LLC, net of cash acquired	0	(33)
Acquisition of product rights, intangible assets, and other related assets	(7,143)	(7,575)
Acquisition of property and equipment, net	(6,589)	(5,738)
Proceeds from the sale of long-lived assets	0	750
Net Cash and Cash Equivalents Used in Investing Activities	(13,732)	(12,596)
Cash Flows From Financing Activities
Payments on borrowings under credit agreements	(2,250)	(2,250)
Series A convertible preferred stock dividends paid	(1,219)	(1,218)
Proceeds from stock option exercises and ESPP purchases	7,027	690
Proceeds from public offering, net of transaction expenses	80,555	0
Treasury stock purchases for restricted stock vests	(4,756)	(1,840)
Net Cash and Cash Equivalents Provided by (Used in) Financing Activities	79,357	(4,618)
Net Change in Cash, Cash Equivalents, and Restricted Cash	139,844	(44,017)
Cash, cash equivalents, and restricted cash, beginning of period	53,234	105,301
Cash, cash equivalents, and restricted cash, end of period	193,078	61,284
Reconciliation of cash, cash equivalents, and restricted cash, beginning of period
Cash and cash equivalents	193,078	56,281
Restricted cash	0	5,003
Cash, cash equivalents, and restricted cash, end of period	193,078	61,284
Supplemental disclosure for cash flow information:
Cash paid for interest, net of amounts capitalized	23,426	14,028
Cash paid for income taxes	930	156
Right-of-use assets obtained in exchange for lease obligations	4,499	0
Supplemental non-cash investing and financing activities:
Acquisition of product rights included in accounts payable	0	1,000
Property and equipment purchased and included in accounts payable	$ 247	$ 204

BUSINESS, PRESENTATION, AND REC

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS	BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS Overview ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, “ANI,” the “Company,” “we,” “us,” or “our”) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The team is focused on delivering growth by scaling up the Rare Disease business through the successful launch of its lead asset, Cortrophin Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our manufacturing capabilities. The Company's three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (“Novitium”) in November 2021. The Company previously completed the transition of the products manufactured or packaged in Oakville to one of the three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement for the purchase and sale of the Oakville, Ontario manufacturing facility (see Note 16). The Company's operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. In May 2023, through a public offering, the Company completed the issuance and sale of 2,183,545 shares of ANI common stock, resul ting in net proceeds after issuance costs of $80.6 million. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company's financial position, results of operations, comprehensive income (loss), and cash flows. The consolidated balance sheet at December 31, 2022 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto previously distributed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”), as filed with the SEC. Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. Foreign Currency The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. We currently have a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and nine months ended September 30, 2023 and 2022. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar. The Company’s asset and liability accounts are translated using the current exchange rate as of the balance sheet date. Shareholders’ equity accounts are translated using historical rates at the balance sheet date. Net revenues and expense accounts are translated using a weighted average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company’s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders’ equity within accumulated other comprehensive income, net of tax. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness. Restructuring Activities The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in our consolidated statements of operations. Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recent Accounting Pronouncements Adopted In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This ASU provides optional expedients and exceptions, that may be elected over time as reference rate reform activities occur, for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance in this ASU was extended in December 2022 when the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 , extending the sunset date under Topic 848 to December 31, 2024 to align the temporary accounting relief guidance with the expected LIBOR cessation. In August 2023, the Company completed the transition of its debt and derivative instruments from LIBOR to Adjusted Term Secured Overnight Financing Rate ("SOFR") and applied the optional expedients in ASC 848 related to contract modifications and changing critical terms of the Company’s hedging relationships. Application of these expedients allowed the Company to preserve presentation of derivatives as qualifying cash flow hedges and to account for the debt modification as a continuation of the existing contract. The adoption of this guidance did not have a material impact on the consolidated financial statements.

REVENUE RECOGNITION AND RELATED

REVENUE RECOGNITION AND RELATED ALLOWANCES	9 Months Ended
REVENUE RECOGNITION AND RELATED ALLOWANCES	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
REVENUE RECOGNITION AND RELATED ALLOWANCES	REVENUE RECOGNITION AND RELATED ALLOWANCES Revenue Recognition The Company recognizes revenue using the following steps: • Identification of the contract, or contracts, with a customer; • Identification of the performance obligations in the contract; • Determination of the transaction price, including the identification and estimation of variable consideration; • Allocation of the transaction price to the performance obligations in the contract; and • Recognition of revenue when we satisfy a performance obligation. Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products we sell is transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days. All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue: Three Months Ended Nine Months Ended Products and Services September 30, September 30, September 30, September 30, (in thousands) Sales of generic pharmaceutical products $ 70,593 $ 53,136 $ 197,623 $ 152,106 Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services 31,502 18,083 87,171 45,951 Sales of rare disease pharmaceutical products 29,734 12,602 70,368 24,096 Total net revenues $ 131,829 $ 83,821 $ 355,162 $ 222,153 Three Months Ended Nine Months Ended Timing of Revenue Recognition September 30, September 30, September 30, September 30, (in thousands) Performance obligations transferred at a point in time $ 131,829 $ 82,318 $ 354,787 $ 219,553 Performance obligations transferred over time — 1,503 375 2,600 Total $ 131,829 $ 83,821 $ 355,162 $ 222,153 In the three and nine months ended September 30, 2023 and 2022, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. The Company recognized an i ncrease of $8.5 million to net revenue from performance obligations satisfied in prior periods during the nine months ended September 30, 2023, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. We recognized a decrease of $2.6 million t o net revenue from performance obligations satisfied in prior periods during the nine months ended September 30, 2022, consisting primarily of revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. As of September 30, 2023, there were no contract assets recorded which were related to revenue recognized based on percentage of completion but not yet billed. For the three and nine months ended September 30, 2023, no deferred revenue was recognized. For the three and nine months ended September 30, 2022, less than $0.1 million of deferred revenue was recognized that was included in deferred revenue as of December 31, 2021. Deferred revenue is included in accrued expenses and other in the unaudited interim condensed consolidated balance sheets. As of September 30, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was $4.0 million, which consists of firm orders for contract manufactured products. We will recognize revenue for these performance obligations as they are satisfied, which is anticipated within six months. Variable consideration Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2023 and 2022, respectively: Accruals for Chargebacks, Returns, and Other Allowances (in thousands) Chargebacks Government Returns Administrative Prompt Balance at December 31, 2021 $ 94,066 $ 5,492 $ 35,831 $ 13,100 $ 4,642 Accruals/Adjustments 480,626 14,104 18,751 30,475 15,746 Credits Taken Against Reserve (480,203) (10,851) (20,598) (28,766) (15,751) Balance at September 30, 2022 (1) $ 94,489 $ 8,745 $ 33,984 $ 14,809 $ 4,637 Balance at December 31, 2022 $ 148,562 $ 10,872 $ 33,399 $ 9,442 $ 6,488 Accruals/Adjustments 437,671 16,998 13,048 40,815 17,024 Credits Taken Against Reserve (501,841) (16,947) (15,009) (39,316) (18,366) Balance at September 30, 2023 (1) $ 84,392 $ 10,923 $ 31,438 $ 10,941 $ 5,146 ______________________________________________ (1) Chargebacks and Prompt Payment Discounts are included as an offset to accounts receivable in the unaudited interim condensed consolidated balance sheets. Administrative Fees and Other Rebates are included as an offset to accounts receivable or as accrued expenses and other in the unaudited interim condensed consolidated balance sheets. Returns are included in returned goods reserve in the unaudited interim condensed consolidated balance sheets. Government Rebates are included in accrued government rebates in the unaudited interim condensed consolidated balance sheets. Credit Concentration ANI's customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and pharmaceutical companies. During the three and nine months ended September 30, 2023, there were four customers that accounted for 10% or more of net revenues. During the three and nine months ended September 30, 2022 , there were three customers that accounted for 10% or more of net revenues. As of September 30, 2023, accounts receivable from these customers totaled 85% of accounts receivable, net. The three customers represent the total percentage of net revenues as follows: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, Customer 1 35 % 23 % 33 % 26 % Customer 2 12 % 17 % 13 % 18 % Customer 3 12 % 16 % 13 % 15 % Customer 4 13 % 7 % 10 % 5 %

RESTRUCTURING

RESTRUCTURING	9 Months Ended
RESTRUCTURING	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
RESTRUCTURING	RESTRUCTURING On March 31, 2023 the Company ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium in November 2021. ANI has completed the transition of the products manufactured or packaged in Oakville to one of the Company's three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement for the purchase and sale of the Oakville, Ontario manufacturing facility (see Note 16). For the nine months ended September 30, 2023, restructuring activities resulted in expenses o f $1.1 million. This i ncl uded $0.2 million of severance and other employee benefit costs and $0.7 million of accelerated depreciation costs and $0.2 million for other miscellaneous costs, respectively. There were no restructuring activities recognized in the three months ended September 30, 2023. As of September 30, 2023, $0.1 million of the severance and other employee benefits are unpaid and accrued. These costs are recorded as restructuring activities, an op erating item, in the accompanying unaudited interim condensed consolidated statements of operations and are part of the Generics, Established Brands, and Other segment. Certain of the severance and other employee benefit costs contain a service requirement, and as such, were accrued over time as they were earned. In conjunction with the exit of the Canadian facility, the Company has determined that the land and building at the Oakville, Ontario, Canada plant will be sold together and met the criteria to be classified as held for sale as of March 31, 2023. The land and building have a net carrying value of $8.0 million, which is presented as assets held for sale on the accompanying unaudited interim condensed consolidated balance sheets. These assets are part of the Generics, Established Brands, and Other segment.

INDEBTEDNESS

INDEBTEDNESS	9 Months Ended
INDEBTEDNESS	Sep. 30, 2023
Debt Disclosure [Abstract]
INDEBTEDNESS	INDEBTEDNESS Credit Facility On November 19, 2021, the Company completed its acquisition (the “Acquisition”) of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021 (the “Merger Agreement”), by and among the Company, Novitium, Nile Merger Sub LLC, a Delaware limited liability company, and certain other parties, with Novitium becoming a wholly owned subsidiary of ANI. On November 19, 2021, the Company, as borrower, entered into a credit agreement (the “Credit Agreement”) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the “Term Facility”) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the “Revolving Facility,” and together with the Term Facility, the “Credit Facility”). The Term Facility proceeds were used to finance the cash portion of the consideration under the Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. Each permits both base rate borrowings (“ABR Loans”) and Eurodollar rate borrowings (“Eurodollar Loans”), plus a spread of (a) 5.00% above the base rate in the case of ABR Loans under the Term Facility and 6.00% above the LIBOR Rate (as defined in the Credit Agreement) in the case of LIBOR loans under the Term Facility and (b) 3.75% above the base rate in the case of ABR Loans under the Revolving Facility and 4.75% above the LIBOR Rate (as defined in the Credit Agreement) in the case of loans under the Revolving Facility. The Credit Facility has a subjective acceleration clause in case of a material adverse effect. As of September 30, 2023, we had not drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions. Amendment No. 1 In July 2023, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement (“Amendment No. 1”). SOFR will be applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and will replace all LIBOR terms. Amendment No. 1 also includes the addition of a credit spread adjustment of 0.11448% for an interest period of one-month duration, 0.26161% for a three-month duration, and 0.42826% for a six-month duration, in addition to SOFR and the applicable margin, as noted above. There were no other changes or modifications to the Credit Agreement. The Company has applied the optional expedients in ASC 848, Reference Rate Reform , and elected to treat the change in the benchmark interest rate to SOFR as a continuation of the existing Credit Agreement and account for the change prospectively. The interest rate under the Term Facility was 11.45% at September 30, 2023. The Company incur red $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum is assessed on any unused portion of the Revolving Facility. The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.’s and its principal domestic subsidiary’s assets and any future domestic subsidiary guarantors’ assets. The Credit Facility is subject to customary financial and nonfinancial covenants. The carrying value of the current and non-current components of the Term Facility as of September 30, 2023 and December 31, 2022 are: Current (in thousands) September 30, December 31, Current borrowing on debt $ 3,000 $ 3,000 Deferred financing costs (2,150) (2,150) Current debt, net of deferred financing costs $ 850 $ 850 Non-Current (in thousands) September 30, December 31, Non-current borrowing on debt $ 291,750 $ 294,000 Deferred financing costs (6,718) (8,331) Non-current debt, net of deferred financing costs and current component $ 285,032 $ 285,669 As of September 30, 2023, outstanding principal was $294.8 million on the Term Facility. Of the $0.7 million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $0.5 million is included in other non-current assets in the unaudited interim condensed consolidated balance sheets, and $0.2 million is included in prepaid expenses and other current assets in the unaudited interim condensed consolidated balance sheets. The contractual maturity of the Term Facility is as follows for the period ending: (in thousands) Term Facility 2023 (remainder of the year) $ 750 2024 3,000 2025 3,000 2026 3,000 2027 285,000 Total $ 294,750 The following table sets forth the components of total interest expense related to the Term Facility during the three and nine months ended September 30, 2023 and 2022, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended (in thousands) September 30, September 30, September 30, September 30, Contractual coupon $ 7,864 $ 6,834 $ 22,834 $ 19,014 Amortization of finance fees 591 592 1,773 1,773 Capitalized interest (142) (31) (440) (80) $ 8,313 $ 7,395 $ 24,167 $ 20,707

DERIVATIVE FINANCIAL INSTRUMENT

DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	9 Months Ended
DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	Sep. 30, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY	DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY At times the Company may use derivative financial instruments to hedge exposure to interest rate risks. All derivative financial instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheet and are classified as current or non-current based on the scheduled maturity of the instrument. When entering into a hedge arrangement and intend to apply hedge accounting, the Company formally documents the hedge relationship and will designate the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. When it is determined that a derivative financial instrument qualifies as a cash flow hedge and is effective, the changes in fair value of the instrument are recorded in accumulated other comprehensive loss, net of tax in the consolidated balance sheets and will be reclassified to earnings when the hedged item affects earnings. In April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage its exposure to changes in LIBOR-based interest rates underlying total borrowings under term facilities related to the Prior Credit Agreement, and the interest rate swap matures in December 2026. Concurrent with the termination of the Prior Credit Agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on November 21, 2021 was novated and Truist Bank is the new counterparty. As described further below, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. The swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility. The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As of September 30, 2023, the notional amount of the interest rate swap was $139.4 million and decreases quarterly by approximately $4.0 million until December 2023, after which it remains static until maturity in December 2026. As of September 30, 2023, the fair value of the interest rate swap asset recorded in other non-current assets in the unaudited interim condensed consolidated balance sheets was $10.0 million. As of September 30, 2023, $14.1 million was recorded in accumulated other comprehensive income, net of tax in the unaudited interim condensed consolidated balance sheets. During the three months ended September 30, 2023 , the change in fair value of the interest rate swaps was a gain of $0.5 million. During the nine months ended September 30, 2023, the change in fair value of the interest rate swaps was a gain of $0.3 million. During the three and nine months ended September 30, 2023, the gain on the interest rate swap of $0.4 million and $1.9 million was recorded in accumulated other comprehensive income (loss), net of tax in the unaudited interim condensed consolidated statements of comprehensive income (loss), respectively. Differences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the three and nine months ended September 30, 2023, $0.7 million and $1.8 million of interest expense was recognized in relation to the interest rate swaps, respectively. Included in this amount for the three months ended September 30, 2023 and 2022 are reclassifications out of accumulated other comprehensive income (loss) of $0.7 million and $0.7 million and during the nine months ended September 30, 2023 and 2022 are $2.1 million and $2.1 million in expense related to terminated and de-designated cash flow hedges. In conjunction with the amendment of the Credit Agreement (see note 4), the Company’s derivative positions automatically transitioned to SOFR, the designated fallback terms, as determined by the International Swaps and Derivatives Association on August 1, 2023. Concurrently, the Company updated its hedge documentation to reflect the change of the benchmark index, which changed solely as a result of reference rate reform. Under ASC 848, Reference Rate Reform , hedge accounting may continue without de-designation if certain criteria are met. For cash flow hedges in which the designated hedged risk is LIBOR (or another rate that is expected to be discontinued), the guidance allows an entity to assert that it remains probable that the hedged forecasted transaction will occur. The Company applied the optional expedient within ASC 848 to conclude the updates to the hedge relationship due to reference rate reform did not have a material impact on the Company's consolidated financial statements.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
EARNINGS (LOSS) PER SHARE	Sep. 30, 2023
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings (loss) per share by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under our Employee Stock Purchase Plan (“ESPP”), and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share. Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator. Earnings (loss) per share for the three and nine months ended September 30, 2023 and 2022 are calculated for basic and diluted earnings (loss) per share as follows: Basic Diluted Basic Diluted (in thousands, except per share amounts) Three Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 2023 2022 2023 2022 Net income (loss) available to common shareholders $ 9,534 $ (9,006) $ 9,534 $ (9,006) $ 16,405 $ (44,871) $ 16,405 $ (44,871) Earnings allocated to participating securities (891) — (881) — (1,629) — (1,615) — Net income (loss) available to common shareholders $ 8,643 $ (9,006) $ 8,653 $ (9,006) $ 14,776 $ (44,871) $ 14,790 $ (44,871) Basic Weighted-Average Shares Outstanding 18,883 16,303 18,883 16,303 17,663 16,238 17,663 16,238 Dilutive effect of common stock options, ESPP, and performance stock units 242 — 160 — Diluted Weighted-Average Shares Outstanding 19,125 16,303 17,823 16,238 Income (loss) per share $ 0.46 $ (0.55) $ 0.45 $ (0.55) $ 0.84 $ (2.76) $ 0.83 $ (2.76)

INVENTORIES

INVENTORIES	9 Months Ended
INVENTORIES	Sep. 30, 2023
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories consist of the following as of: (in thousands) September 30, 2023 December 31, 2022 Raw materials $ 58,748 $ 67,726 Packaging materials 8,870 7,720 Work-in-progress 3,577 1,889 Finished goods 35,395 28,020 Inventories $ 106,590 $ 105,355 Vendor Concentration

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill As a result of the 2013 merger with BioSante Pharmaceuticals, Inc. (“BioSante”), goodwill of $1.8 million was recognized. As a result of the acquisition of WellSpring Pharma Services Inc. in 2018, goodwill of $1.7 million was recognized. From the acquisition of Novitium in 2021, goodwill of $24.6 million was recognized. As of September 30, 2023, the Company had two operating segments, which were also deemed the Company's two reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. All of the goodwill is recorded in our Generics, Established Brands, and Other reporting unit. Goodwill is reviewed for impairment at least annually, at October 31st, or more frequently if a triggering event occurs between impairment testing dates. The Company’s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is “more likely than not” that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of our reporting unit to its respective carrying value, including its goodwill. If it is determined that it is “not likely” that the fair value of the reporting unit is less than its carrying value, then no further testing is required. There have been no events or changes in circumstances that would have reduced the fair value of the Generics, Established Brands, and Other reporting unit below its carrying value during the nine months ended September 30, 2023 and 2022, no impairment charges have been recognized. Intangible Assets The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows: September 30, 2023 December 31, 2022 Remaining Weighted Average (in thousands) Gross Carrying Accumulated Gross Carrying Accumulated Definite-Lived Intangible Assets: Acquired ANDAs intangible assets $ 209,780 $ (94,139) $ 195,862 $ (75,606) 5.4 years NDAs and product rights 242,372 (179,193) 242,372 (162,188) 3.2 years Marketing and distribution rights 17,157 (14,031) 17,157 (13,309) 3.3 years Non-compete agreement 624 (624) 624 (602) — years Customer relationships 24,900 (6,818) 24,900 (4,150) 5.1 years Total Definite-Lived Intangible Assets 494,833 (294,805) 480,915 (255,855) 4.6 years Indefinite-Lived Intangible Assets: In process research and development 19,800 — 26,575 — Indefinite Total Intangible Assets, net $ 514,633 $ (294,805) $ 507,490 $ (255,855) (1) Weighted average amortization period as of September 30, 2023. Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (“ANDAs”), New Drug Applications (“NDAs”) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from seven During the three months ended September 30, 2023, approximately $6.8 million was reclassified from indefinite-lived in-process research and development (“IPR&D”) to acquired ANDAs and approximately $2.8 million of acquired ANDA intangible assets were capitalized related to the August 14, 2023 transaction with Slayback Pharma Limited Liability Company (“Slayback”), a New Jersey-based company focused on complex generic and specialty pharmaceutical products (see Note 13). Amortization expense for definite-lived intangibles was $13.3 million and $12.5 million for the three months ended September 30, 2023 and 2022, respectively, and $39.0 million and $36.9 million for the nine months ended September 30, 2023 and 2022, respectively. No impairment losses were recognized in the three and nine months ended September 30, 2023. In the nine months ended September 30, 2022, an impairment charge of approximately $0.1 million was recognized in relation to an ANDA asset. Indefinite-lived intangible assets other than goodwill include primarily IPR&D projects. IPR&D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&D project is completed (generally upon receipt of regulatory approval), then the IPR&D will be accounted for as a definite-lived intangible asset. Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets when events or circumstances indicate that the carrying value of the assets may not be recoverable. No impairment losses were recognized in the three and nine months ended September 30, 2023 and 2022, respectively. Expected future amortization expense for definite-lived intangible assets is as follows: (in thousands) 2023 (remainder of the year) $ 13,319 2024 49,554 2025 46,319 2026 33,001 2027 24,089 2028 and thereafter 33,746 Total $ 200,028

MEZZANINE AND STOCKHOLDERS' EQU

MEZZANINE AND STOCKHOLDERS' EQUITY	9 Months Ended
MEZZANINE AND STOCKHOLDERS' EQUITY	Sep. 30, 2023
Stockholders' Equity Note [Abstract]
MEZZANINE AND STOCKHOLDERS' EQUITY	MEZZANINE AND STOCKHOLDERS’ EQUITY Stockholders’ Equity Authorized shares The Company is authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at September 30, 2023. There were 20.7 million and 20.4 million shares of common stock issued and outstanding as of September 30, 2023, respectively, and 17.6 million and 17.5 million shares of common stock issued and outstanding as of December 31, 2022, respectively. Class C Special Stock There were 11 thousand shares of class C special stock issued and outstanding as of September 30, 2023 and December 31, 2022. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of our assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights. Mezzanine Equity PIPE Shares Concurrently with the execution of the Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the “PIPE Investor”), pursuant to which the PIPE Investor purchased 25,000 shares of Series A Convertible Preferred Stock (the “PIPE Shares”), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely within the Company's control. The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. The PIPE Shares are convertible into common shares at the conversion price of $41.47 (i) beginning two years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of September 30, 2023, the PIPE shares are currently convertible into a maximum of 602,901 shares of common stock. In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Company's common stock, the greater of (i) the PIPE Shares’ purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into common stock. The PIPE Shares will have voting rights, voting as one series with the holders of common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Certificate”) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control, the PIPE Shares will be redeemed at the greater of (i) the PIPE Shares’ purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the PIPE Investor would have received if it had converted into shares of common stock.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
STOCK-BASED COMPENSATION	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Employee Stock Purchase Plan In July 2016, we commenced administration of the ANI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan. As of September 30, 2023, we had 0.1 million shares of common stock available under the ESPP. Under the ESPP, participants can purchase common shares of the Company's stock at a 15% discount on the lowest share price on the first day of the purchase period or the last day of the purchase period. The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of sales $ 16 $ 11 $ 46 $ 40 Research and development 14 10 33 31 Selling, general, and administrative 109 82 251 142 $ 139 $ 103 $ 330 $ 213 Stock Incentive Plan Equity-based service awards are granted under the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the “2022 Plan”), which was approved by its stockholders at the 2022 Annual Meeting of Stockholders (the “Annual Meeting”) held on April 27, 2022. During the 2023 Annual Meeting of Stockholders held on May 23, 2023, stockholders approved an amendment of the 2022 Plan (the “ 2023 Stock Plan Amendment ” ). The 2023 Stock Plan Amendment increased the shares authorized for issuance under the 2022 Plan by 750,000 additional shares. As of September 30, 2023, 1.1 million shares of common stock were available for issuance under the 2022 Plan. Stock Options : Outstanding stock options to purchase shares of common stock are granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of one From time to time, stock options are granted to employees through an inducement grant outside of our 2022 Plan to induce prospective employees to accept employment with the Company (the “Inducement Grants”). The options are granted at an exercise price equal to the fair market value of a share of common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of our stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. Restricted Stock Awards : Restricted stock awards (“RSAs”) granted to employees generally vest over a period of four years and RSAs granted to non-officer directors generally vest over a period of one year. During the vesting period, the recipient of the RSAs has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of our stock on the date of grant. Upon vesting, unrestricted shares of common stock are delivered to employees and directors. Performance-Based Restricted Stock Units : Awards may also be issued in the form of Performance Stock Units (“PSUs”). PSUs represent the right to receive an amount of cash, a number of shares of common stock or a combination of both, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a three three three three The other 50% of the PSUs were performance based restricted stock units (“PRSUs”), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over three three three The following table summarizes stock-based compensation expense incurred under the 2022 Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of sales $ 166 $ 134 $ 475 $ 393 Research and development 225 186 638 531 Selling, general, and administrative 4,914 3,447 13,588 9,725 $ 5,305 $ 3,767 $ 14,701 $ 10,649 A summary of stock option, RSA, and PSU activity under the 2022 Plan and Inducement Grants during the nine months ended September 30, 2023 is presented below: (in thousands) Options Inducement Grants PSUs RSAs Outstanding at December 31, 2021 747 241 — 707 Granted 36 — — 723 Options Exercised/RSAs Vested (16) — — (234) (1) Forfeited (58) — — (46) Expired — — — — Outstanding at September 30, 2022 709 241 — 1,150 Outstanding at December 31, 2022 907 241 — 1,141 Granted 3 — 85 648 Options Exercised/RSAs Vested (151) — — (369) (2) Forfeited (28) — (1) (76) Expired — — — — Outstanding at September 30, 2023 731 241 84 1,344 ______________________________________________ (1) Includes 63 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $1.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. (2) Includes 111 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.8 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.

INCOME TAXES

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. As of September 30, 2023, we had provided a valuation allowance against consolidated net deferred tax assets of $0.4 million, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions. We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements. We recognize interest and penalties accrued on any unrecognized tax exposures as a component of income tax expense; we did not have any such amounts accrued as of September 30, 2023 and December 31, 2022. We are subject to taxation in various U.S. jurisdictions, Canada, and India and all of our income tax returns remain subject to examination by tax authorities due to the availability of NOL carryforwards. For interim periods, we recognize an income tax benefit (provision) based on our estimated annual effective tax rate, calculated on a worldwide consolidated basis, expected for the entire year. The interim annual estimated effective tax rate is based on the statutory tax rates then in effect, as adjusted for estimated changes in estimated permanent differences and excludes certain discrete items whose tax effect, when material, are recognized in the interim period in which they occur. These changes in permanent differences and discrete items result in variances to the effective tax rate from period to period. We also have elected to exclude the impacts from significant pre-tax non-recognized subsequent events from our interim estimated annual effective rate until the period in which they occur. Our estimated annual effective tax rate changes throughout the year as our on-going estimates of pre-tax income, and changes in permanent differences are revised, and as discrete items occur. Global Intangible Low-Taxed Income (“GILTI”), as defined in the Tax Cuts and Jobs Act of 2017, generated from our Canadian and Indian operations is subject to U.S. taxes, with certain defined exemptions, thresholds and credits. For financial reporting purposes we have elected to treat GILTI inclusions as a period cost. For the three months ended September 30, 2023, the Company recognized an income tax expense of $1.6 million. The Company's effective tax rate was 13.6% after discrete items f or the three months ended September 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and stock based compensation. For the three months ended September 30, 2022, the Company recognized an income tax benefit of $3.6 million . The income tax benefit resulted from applying an estimated annual worldwide effective tax benefit rate of 29.6% to pre-tax consolidated loss of $12.2 million reported during the period. There were no material discrete items occurring during the three months ended September 30, 2022. For the nine months ended September 30, 2023 , the Company recognized an income tax expense of $1.3 million . The Company's effective tax rate was 6.9% after discrete items for the nine months ended September 30, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and stock based compensation. For the nine months ended September 30, 2022, the Company recognized an income tax benefit of $13.3 million. The income tax benefit resulted from applying an estimated annual worldwide effective tax rate of 23.3% to pre-tax consolidated loss of $56.9 million reported during the period. There were no material discrete items occurring during the nine months ended September 30, 2022. We expect that recent tax law changes contained in Inflation R eduction Act and the Creating Helpful Incentives to Produce Semiconductors and Science Act of 2022 (“CHIPS Act”) will not have a material impact on the provision for income taxes.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Operating Leases In April 2023, the Company entered into an agreement to lease additional warehouse space in East Windsor, New Jersey. The lease has a term of five years, and was classified as an operating lease. The lease was capitalized on the accompanying unaudited condensed consolidated balance sheets. Government Regulation Products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (“DEA”), the Food and Drug Administration (“FDA”), the Centers for Medicare and Medicaid Services (“CMS”), the Central Drugs Standard Control Organization (“CDSCO”), The Narcotics Control Bureau (“NCB”), and India’s Ministry of Health and Family Welfare (“MoHFW”). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of the Company's products. The DEA and NCB maintain oversight over products that are considered controlled substances. Unapproved Products Three products, Esterified Estrogen with Methyltestosterone (“EEMT”), Opium Tincture, and Thyroid Tablets are marketed without approved NDAs or ANDAs. If the FDA took enforcement action against the Company, we may be required to seek FDA approval for the group of products or withdraw them from the market. During the three months ended September 30, 2023 and 2022, net revenues for these products totaled $9.2 million and $3.1 million, respectively. During the nine months ended September 30, 2023 and 2022, net revenues for these products totaled $16.4 million and $10.0 million, respectively. In addition, one group of products that are manufactured on behalf of a contract customer is marketed by that customer without an approved NDA. If the FDA took enforcement action against such customer, the customer may be required to seek FDA approval for the group of products or withdraw them from the market. Contract manufacturing revenues for the group of unapproved products for the three months ended September 30, 2023 and 2022 were less than $0.1 million and $1.0 million, respectively. Contract manufacturing revenues for the group of unapproved products for the nine months ended September 30, 2023 and 2022 were $1.1 million and $2.1 million, respectively. Legal proceedings The Company is involved, and from time to time may become involved, in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition. Some of these matters with which we are involved are described below and in our 2022 Form 10-K, and unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters. Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us. Legal fees for litigation-related matters are expensed as incurred and included in the condensed consolidated statements of operations under the selling, general, and administrative expense line item. Commercial Litigation On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Company’s January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneys’ fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York as In re Bystolic Antitrust Litigation, Case No. 20-cv-005735 (LJL). On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendants’ motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit. The matter is fully briefed and oral arguments are scheduled for December 6, 2023. ANI continues to dispute any liability in this matter. On March 24, 2021, Azurity Pharmaceuticals, Inc. (“Azurity”) filed a complaint in the United States District Court for the District of Minnesota against ANI, asserting that ANI’s vancomycin hydrochloride oral solution drug product infringes U.S. Patent No. 10,688,046. The complaint sought injunctive relief, damages, including lost profits and/or royalty, treble damages, and attorneys’ fee and costs. On February 15, 2022, the Company entered into a settlement agreement with Azurity to resolve all claims related to this action. Under the terms of the agreement, Azurity granted ANI a non-exclusive, non-transferable, non-sublicensable, royalty-bearing license under its patents to sell ANI product in the United States and dismissed the action with prejudice. In exchange, ANI paid Azurity $1.9 million of royalties from past sales and will pay Azurity a royalty equal to 20% of gross margin of sales of the ANI product for a contractually defined term. On April 1, 2021, United Therapeutics Corp. and Supernus Pharmaceuticals, Inc. (“UTC/Supernus”) filed a complaint in the United States District Court for the District of Delaware against ANI, asserting that ANI’s proposed Treprostinil extended release drug product, which is subject to ANI’s Abbreviated New Drug Application No. 215667, infringes U.S. Patent Nos. 7,417,070, 7,544,713, 8,252,839, 8,349,892, 8,410,169, 8,747,897, 9,050,311, 9,278,901, 9,393,203, 9,422,223, 9,593,066 and 9,604,901 (“the Asserted Patents”). The complaint seeks injunctive relief , attorneys' fee and costs. ANI filed its answer and counterclaims on May 28, 2021, denying UTC/Supernus’ allegations and seeking declaratory judgment that ANI has not infringed any valid and enforceable claim of the Asserted Patents, that the Asserted Patents are invalid, and an award of attorneys’ fees and costs. On May 26, 2022, the parties’ respective claims and counterclaims were dismissed pursuant to a confidential settlement agreement. On October 3, 2022, Azurity filed a complaint in the United States District Court for the District of New Jersey against Novitium, seeking a declaratory judgment that Novitium’s manufacture, use, sale, importation and/or offer to sell Bionpharma Inc.’s (“Bionpharma”) enalapril maleate oral solution drug product (the “Product”) would infringe U.S. Patents Nos. 11,040,023 and 11,141,405 (the “Novitium Action”). The complaint seeks injunctive relief, and an award of Azurity’s costs and expenses. On October 12, 2022, Bionpharma filed a motion in the New Jersey court to intervene on Novitium’s behalf in the litigation and on October 14, 2022, Novitium and Bionpharma jointly moved to transfer venue to the District of Delaware. Transfer was granted on January 20, 2023. On March 27, 2023, the transferred Novitium Action (assigned Delaware Civil Action No. 23-163-MSG) was consolidated with the Delaware Third Wave Suits against Bionpharma (Civil Action Nos. 21-1286-MSG, 21-1455-MSG), which include Azurity’s infringement claims against Bionpharma involving the same patents asserted in the Novitium Action, as well as Bionpharma’s antitrust claims against Azurity. On August 3, 2023, Azurity filed an amended complaint against Novitium seeking damages for supplying Bionpharma's ANDA product. On October 31, 2023, the court denied Azurity's request for a stay and court-ordered mediation of the patent infringement and antitrust cases, and entered a scheduling order only for the antitrust case. The court stated that the schedule may be modified to incorporate dates for patent discovery and trial in the patent infringement case pending the outcome of the motion for rehearing in the related appeal in Azurity v. Alkem, No. 2023-1540 (Fed. Cir.). On November 1, 2023, the court denied Azurity's request for a rehearing in the Alkem case. Bionpharma has agreed to indemnify Novitium under the terms of its manufacturing and supply agreement for any damages, costs, and expenses relating to actual or alleged infringement of intellectual property rights or sale of the Product by Bionpharma. ANI and Novitium dispute any liability in this matter. On September 29, 2023, Orphalan SA filed a complaint in the United States District Court for the District of Delaware against Novitium, asserting that Novitium's proposed triethylenetetramine tetrachloride drug product, which is subject to Novitium's Abbreviated New Drug Application No. 218493, infringes U.S. Patent Nos. 10,988,436 and 11,072,577. The complaint seeks damages, injunctive relief, attorneys' fees and costs. Novitium disputes any liability in this matter. Ranitidine Related Litigation State of New Mexico Litigation . In July 2020, ANI and Novitium were served with a complaint brought in the First Judicial Court, County of Santa Fe, State of New Mexico by the Office of the Attorney General of the State of New Mexico against manufacturers and sellers of ranitidine products. The complaint asserts a public nuisance claim and a negligence claim against the generic ranitidine manufacturer defendants, including ANI and Novitium. As damages for the nuisance claim, New Mexico asks that the defendants fund this medical monitoring program. With respect to the nuisance claim, New Mexico asserts that it paid for ranitidine products through state-funded insurance and health-care programs. On December 15, 2020, the case was removed to federal court and transferred to the In re Zantac multidistrict litigation (“MDL”) pending in the United States District Court for the Southern District of Florida. On February 26, 2021, New Mexico moved for remand to state court. The MDL court granted the remand motion on February 25, 2021. On April 16, 2021, New Mexico filed an amended complaint in the New Mexico First Judicial District Court in Santa Fe County. It did not name ANI in the amended complaint, effectively voluntarily dismissing ANI from the action. Novitium is named as a Defendant in the amended complaint. On September 1, 2023, the court entered an order dismissing Novitium without prejudice. Federal Court Personal Injury Litigation . In June 2020, ANI was served with a personal injury complaint in the case of Koepsel v. Boehringer Ingelheim Pharmaceuticals, et al. , MDL No. 20-MD-2924, Case No. 9:20-cv-80882-RLR, filed in the United States District Court for Southern District of Florida, in which the plaintiff alleges that he developed kidney cancer in 2018 as a result of taking over the counter medication containing ranitidine. The Koepsel action was filed within the existing MDL concerning ranitidine-containing drugs pending in the Southern District of Florida, In re Zantac MDL , 20 MDL 2924. A Master Personal Injury Complaint (“MPIC”) in that MDL that was filed on June 22, 2020 also named ANI and Novitium as defendants. ANI was dismissed from the Koepsel case on August 21, 2020 and was dismissed from the MPIC on September 8, 2020. On December 31, 2020, after ANI was dismissed, the district court dismissed the MPIC claims against generic manufacturer defendants partially with prejudice and partially with leave to replead. The failure to warn and design defect claims were dismissed with prejudice on preemption grounds. An Amended MPIC was filed on February 8, 2021, which did not name ANI but did name Novitium. By opinion dated July 8, 2021, the district court dismissed all claims against the generic manufacturer defendants with prejudice on preemption grounds. That decision is on appeal to the Eleventh Circuit Court of Appeals. In addition, by opinion and order dated December 6, 2022, the district court granted the brand manufacturer defendants’ Daubert motion to exclude the plaintiffs’ expert testimony on general causation for the “designated cancers” that the plaintiffs’ leadership team claimed to be caused by ranitidine. The district court also granted the brand manufacturer defendants’ motion for summary judgment because the plaintiffs had failed to produce admissible primary evidence of general causation. The plaintiffs have appealed to the Eleventh Circuit Court of Appeals. ANI and Novitium were named in other individual personal injury complaints filed in the MDL in which plaintiffs allege that they developed cancer after taking prescription and over the counter medication containing ranitidine. ANI was served with complaints in five of those additional cases: Cooper v. Boehringer Ingelheim Pharmaceuticals, et al. , MDL No. 20-MD-2924, Case No. 9:20-cv-81130-RLR (served September 30, 2020), Lineberry v. Amneal Pharmaceuticals, LLC, et al. , MDL No. 20-MD-2924, Case No. 9:20-cv-81079-RLR (served August 20, 2020), Lovette v. Amneal Pharmaceuticals, LLC, et al. , MDL No. 20-MD-2924, Case No. 9:20-cv-81040-RLR (served August 26, 2020), Hightower v. Pfizer, et al, MDL No. 20-MD-2924, Case No. 9-20-cv-82214-RLR (served December 16, 2020) and Bird v. Boehringer Ingelheim Pharmaceuticals, et al. , MDL No. 20-MD-2924, Case No. 9-20-cv-80837-RLR (served December 30, 2020). ANI informed counsel for the plaintiffs that ANI did not sell an over the counter ranitidine product and sold a generic prescription ranitidine product for a limited two-month period of time, from July 2019 to September 2019. Each of the plaintiffs in the five pending cases alleges a cancer diagnosis prior to the time that ANI sold ranitidine, and ANI informally sought dismissal from these cases on that basis. ANI was voluntarily dismissed from the Cooper , Lineberry and Lovette actions on November 20, 2020, from the Bird action on March 15, 2021, and from the Hightower action on March 29, 2021. Prior to the district court’s July 8, 2021 preemption decision, Novitium had been named in 158 short form complaints filed by claimants in the MDL. Those complaints were effectively dismissed with prejudice with the MPIC on July 8, 2021. Counsel for the plaintiffs have been notified that Novitium did not sell an over the counter ranitidine product and sold a generic prescription ranitidine product for a limited period of time, from December 2018 until September 2019. Novitium’s product was voluntarily recalled in October 2019. Out of the 158 short form complaints, approximately 114 plaintiffs either were diagnosed with cancer before Novitium began manufacturing the product, only took over the counter ranitidine, or took ranitidine before Novitium began manufacturing it. Two of those 114 plaintiffs dismissed Novitium from their short form complaints. In light of the Court’s dismissal of all claims with prejudice, Novitium has not pursued dismissal of the short form complaints against it at this time. Following the district court’s Daubert decision, plaintiffs began filing additional short form complaints in the MDL. Novitium currently is named as a defendant in more than 700 short form complaints. On June 1, 2023, ANI was provided with “courtesy service” of nine short form complaints filed in the Zantac MDL 2924 in the Southern District of Florida, which purport to assert personal injury claims against ANI relating to ranitidine products. The plaintiffs are: (1) David L. Eads, Case No. 3:23-cv-23009-XXXX (alleged to have been diagnosed with cancer in 2016, before ANI began selling generic prescription ranitidine products); (2) Luis E. Acevedo, Case No. 3:23-cv-80534-XXXX (alleged to have been diagnosed with cancer in June 2019, before ANI began selling generic prescription ranitidine products); (3) Shellie Green, Case No. 3:23-cv-23032-XXXX; (4) Patricia Manders, individually and on behalf of the Estate of Jerry Manders, Case No. 3:23-cv-23026-XXXX (alleged to have died in March 2019, before ANI began selling generic prescription ranitidine products); (5) Christine Behrman, individually and on behalf of the Estate of Ralph Behrman, Case No. 3:23-cv-23016-XXXX; (6) Wendy Kelfer, individually and on behalf of the Estate of Sidney Kelfer, Case No. 3:23-cv-23029-XXXX; (7) Helen Romero, individually and on behalf of the Estate of Deborah Kilborn, Case No. 3:23-cv-23008-XXXX; (8) Jeffrey Eugene Guidry, Case No. 3:23-cv-22980-XXXX; and (9) Ruth Copeland, Case No. 3:23-cv-22973-XXXX (alleged to have been diagnosed with cancer in 2015, before ANI began selling generic prescription ranitidine products). The service cover letter acknowledges that the Zantac MDL is closed due to the pending appeal and the court is not issuing summonses. The plaintiffs have taken multiple appeals from decisions issued by the district court in the MDL to the Eleventh Circuit. On September 8, 2023, the Eleventh Circuit remanded a subset of the MDL appeals back to the district court for entry of final judgments pursuant to Rule 58. The defendants filed a motion with the Eleventh Circuit to remand a similarly situated appeal for similar entry of a final judgment. In addition, the defendants are seeking a stay from the Eleventh Circuit of all non-remanded related appeals in order to have all of the related appeals decided together. ANI and Novitium dispute any liability in these matters. State Court Personal Injury Litigation Illinois . On February 3, 2022, a complaint was filed in Cook County, Illinois, naming Novitium as a defendant. The complaint incorrectly identifies Novitium as a “repackager.” The case is styled Ross v. Boehringer Ingelheim Pharmaceuticals, Inc., et. al . The complaint asserts claims of strict liability/failure to warn, strict liability/design defect, negligent failure to warn, negligent product design, general negligence, negligent misrepresentation, breach of express and implied warranties, and unjust enrichment. The plaintiff alleges that he was diagnosed with prostate cancer in 2017, before Novitium began selling generic ranitidine products, and that he took over the counter ranitidine that he purchased at Walgreens from 2008 to 2019. At this point, the allegations show that the plaintiff’s alleged cancer injury could not have come from a Novitium product. The generic manufacturer defendants filed a motion to dismiss on preemption grounds. That motion is pending. In August 2022, the Keller Postman law firm commenced six multi-plaintiff actions in Illinois state court naming generic ranitidine manufacturers, including ANI and/or Novitium, as defendants. Those cases are: (1) Jodee Gillespie v. Walgreen Co., et. al. , Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 2022LA001007 (naming both Novitium and ANI); (2) John Jackson v. Walgreen Co., et. al. , Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 2022LA001012 (naming Novitium); (3) Ayesha Salahuddin v. Walgreen Co., et. al., Circuit Court of the Twentieth Judicial Circuit, St. Clair County, Illinois, Case No. 22LA0709 (naming Novitium); (4) Lashanda McGruder v. Walgreen Co., et. al., Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 22LA0710 (naming both Novitium and ANI); (5) Richard Devriendt v. Walgreen Co., et. al., Circuit Court of Cook County, Illinois, Case No. 2022L007429 (naming Novitium); (6) Anthony Stigger v. Walgreen Co., et. al., Circuit Court of Cook County, Illinois, Case No. 2022L007396 (naming both Novitium and ANI). The complaints allege causes of action for failure to warn, design defect, general negligence, loss of consortium and wrongful death. Pursuant to an Order of the Illinois Supreme Court dated October 25, 2022, the pending ranitidine personal injury actions in Illinois have been consolidated in Cook County for coordinated pre-trial proceedings. Those pre-trial proceedings are pending in the Circuit Court of Cook County. On January 12, 2023, the court directed the plaintiffs to dismiss the multi-plaintiff actions and refile each individual plaintiff action under a separate case number. At a status conference held on February 16, 2023, the court required that the plaintiffs re-file within 60 days. The court also authorized use of a master complaint. Plaintiffs filed a master long-form complaint on March 9, 2023 naming Novitium as a defendant. ANI is not named as a defendant. The Keller Postman firm has confirmed that its clients are no longer pursuing claims against ANI. When the court ruled the cases needed to be re-filed as single-plaintiff cases, Novitium was never served. The counts in the master complaint include strict liability for failure to warn/design defects, general negligence, negligent misrepresentation, negligent storage and transport, apparent manufacturer liability, common law fraud, unjust enrichment, civil conspiracy, and breach of express and implied warranties. The complaint further alleges violations of the Illinois Consumer Fraud Act. Pursuant to the court’s standing order, the generic defendants filed a motion to dismiss pursuant to IL 2-615 (failure to state a claim on the face of the complaint) on April 13, 2023, claiming preemption by federal law. On August 10, 2023, the court dismissed all claims against the generic defendants with prejudice on preemption grounds. California. In August and September 2022, the Keller Postman law firm commenced seven multi-plaintiff actions in California state court, Alameda County, naming generic ranitidine manufacturers, including ANI and/or Novitium, as defendants. Those cases are: (1) Carlos Ascencio v. ANI Pharmaceuticals, et. al., Superior Court of California, County of Alameda, Case. No. 22CV016230 (naming both Novitium and ANI); (2) Andre Lebeau v. Actavis Mid Atlantic, LLC et. al., Superior Court of California, County of Alameda, Case No. 22CV016448 (naming Novitium); (3) Roque Torres v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016338 (naming both Novitium and ANI); (4) Deborah Hinds v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016123 (naming both Novitium and ANI); (5) Mark Cruz v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016338 (naming both Novitium and ANI); (6) Bent Olsen v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016402 (naming both Novitium and ANI); (7) John Norman v. Actavis Mid Atlantic, LLC, et. al., Superior Court of California, County of Alameda, Case No. 22CV018334 (naming Novitium). The complaints allege causes of action for failure to warn, design defect, general negligence, loss of consortium and wrongful death. By stipulation and order dated December 28, 2022, the cases were transferred to an existing civil case coordination docket for pretrial proceedings (JCCP) pending in Alameda County. By order dated January 19, 2023, the court ordered that counsel for the plaintiffs must dismiss the individual plaintiffs (other than the first-named plaintiff) from each of the multi-plaintiff complaints and that each of the dismissed plaintiffs must re-file their claims in a single plaintiff complaint. As of April 25, 2023, ANI and Novitium had not yet been served with any of these single-plaintiff complaints. As of April 25, 2023, the Company is aware of three single-plaintiff cases in which Novitium is named as a defendant: David Duncan v. GSK Holdings , No. T23-507 ; Charmaine Sili v. GSK Holdings , No. T23-355; and Charles Crippen v. Boehringer, No. T23-349. At this time, none of the generic defendants have been served with any complaints. On September 21, 2023, the plaintiff leadership filed a master complaint in the JCCP. The master complaint does not name any generic defendants. However, the short form complaints allow individual plaintiffs to name "other defendants," leaving open the option for individual plaintiffs to name generic manufacturers as defendants. Pennsylvania . In September 2022, two single-plaintiff complaints were filed in Pennsylvania state court, Philadelphia County, naming Novitium as a defendant: (1) William Titus v. Glaxo SmithKline LLC, et. al. , Court of Common Pleas, Philadelphia County, Pennsylvania, Case No. 220902548; and (2) Jodi Woodard v. Ajanta Pharma USA, Inc., et. al. , Court of Common Pleas, Philadelphia County, Pennsylvania, Case No. 220902329. These complaints allege causes of action for negligence, failure to warn, negligent storage and transportation, breach of express and implied warranties, negligent misrepresentation, and fraud. On February 16, 2023, the Pennsylvania plaintiffs filed a consolidated long-form complaint against the generic defendants, Plaintiffs v. Actavis, et. al. Civil Action No. 1364. The long-form complaint names Novitium as a defendant. The long form complaint asserts causes of action for negligence, failure to warn, negligent storage and transportation, breach of express warranties, breach of implied warranties, negligent misrepresentation, fraud, strict products liability, wrongful death and survivor actions, and loss of consortium. The complaint includes a prayer for punitive damages. The generic defendants filed their preliminary objections to Plaintiffs’ consolidated long-form generic complaint on March 20, 2023. The court sustained the generics’ objection that plaintiffs’ failure to warn/design defect claims were preempted by federal law; therefore, all allegations related to failure to warn/design defects are dismissed. The court also sustained the generics’ preliminary objections relating to the counts of strict liability-design defect and breach of implied warranty to the extent Pennsylvania substantive law applies. The court noted the substantive law of another state may not conflict with federal law, and, further, strict liability and breach of implied warranty causes of action of another state may apply in individual cases. This is a determination that can only be made after short form complaints are filed. It is the generics’ position that the court’s ruling on the preliminary orders effectively dismissed the generics from the case unless and until a non-resident plaintiff names a generic in a short form complaint. Out of an abundance of caution, however, the generics, including Novitium, all filed answers to the longform complaint in June 2023. ANI and Novitium dispute any liability in these matters. Other Industry Related Matters On or about September 20, 2017, the Company and certain of its employees were served with search warrants and/or grand jury subpoenas to produce documents and possibly testify relating to a federal investigation of the generic pharmaceutical industry. We have been cooperating and intend to continue cooperating with the investigation. However, no assurance can be given as to the timing or outcome of the investigation.

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES	9 Months Ended
FAIR VALUE DISCLOSURES	Sep. 30, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE DISCLOSURES	FAIR VALUE DISCLOSURES Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework that prioritizes and ranks the level of observability of inputs used in measuring fair value. The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of our funds. The fair value of short-term financial instruments (primarily accounts receivable, prepaid expenses, accounts payable, accrued expenses, and other current liabilities) approximate their carrying values because of their short-term nature. The Term Facility bears an interest rate that fluctuates with the changes in SOFR and, because the variable interest rates approximate market borrowing rates available to us, we believe the carrying values of these borrowings approximated their fair values at September 30, 2023. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Contingent Value Rights The contingent value rights (“CVRs”), which were granted coincident with the merger with BioSante expired during June 2023, were considered contingent consideration and were classified as liabilities, and there were no payments made pursuant to the terms of the CVR agreement. Interest Rate Swap The fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve (see Note 5). The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 5, the fair value of the interest rate swap was $10.0 million as of September 30, 2023, and was classified as a non-current asset. Contingent Consideration In connection with the acquisition of Novitium, the Company may be obligated to pay up to $46.5 million in additional consideration related to the achievement of certain milestones, such as milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future. The discounted cash flow method used to value this contingent consideration includes inputs which are classified as Level 3 inputs, as the inputs are not based on readily available market data. The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Payment Type Valuation Technique Unobservable Input Assumptions Profit-based milestone payments Probability-weighted discounted cash flow Discount rate 13.0% Projected fiscal year of payment 2025-2035 Product development-based milestone payments Probability-weighted discounted cash flow Discount rate 9.0% - 13.0% Probability of payment 100.0% Projected fiscal year of payment 2024 The following table presents the changes in contingent consideration balances classified as Level 3 for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Beginning balance $ 37,054 $ 30,958 $ 35,058 $ 31,000 Measurement period adjustment — — — 300 Change in fair value (2,555) 2,476 (559) 2,134 Ending balance $ 34,499 $ 33,434 $ 34,499 $ 33,434 The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022, by level within the fair value hierarchy: (in thousands) Fair Value at Level 1 Level 2 Level 3 Assets Interest rate swap $ 10,014 $ — $ 10,014 $ — Liabilities Contingent consideration $ 34,499 $ — $ — $ 34,499 Description Fair Value at Level 1 Level 2 Level 3 Assets Interest rate swap $ 8,759 $ — $ 8,759 $ — Liabilities Contingent consideration $ 35,058 $ — $ — $ 35,058 Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis There are no financial assets or liabilities that are measured at fair value on a non-recurring basis. Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis There are no non-financial assets or liabilities that are measured at fair value on a recurring basis. Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis Long-lived assets, including property, plant, and equipment, right-of-use (“ROU”) assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis. No such fair value impairment was recognized in the three and nine months ended September 30, 2023 and 2022. Acquired Non-Financial Assets Measured at Fair Value On August 14, 2023, the Company acquired one ANDA and registered patents and pending patent applications from Slayback Pharma Limited Liability Company for total consideration of $3.0 million (see Note 8). The Company also acquired an NDA which has yet to be filed. The transaction was funded from cash on hand. The transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. Intangible assets amounted to $2.8 million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDA will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to September 30, 2023, and therefore no impairment loss was recognized for the three and nine months ended September 30, 2023. During the second quarter of fiscal 2023, the Company acquired two ANDAs and one pipeline product from the Chapter 7 Trustee for the estates of Akorn Holding Company and certain of its affiliates for total consideration of $4.8 million. The transaction was funded from cash on hand. This transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. The product portfolio included two commercial products and one pipeline product. The Company recognized $4.3 million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDAs will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to September 30, 2023, and therefore no impairment loss was recognized for the three and nine months ended September 30, 2023.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS On March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which 25,000 shares were purchased for $1,000 per share for an aggregate purchase price of $25.0 million on November 19, 2021. The Chairman of the Company's board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor. In connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam and Chad Gassert. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company’s board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (“Scitus”), which provides clinical research services to Novitium; majority interest in SS Pharma LLC (“SS Pharma”), which acquires and supplies API to Novitium; majority interest in Esjay Pharma LLC (“Esjay”), which provided research and development and facilities consulting services; and a minority interest in Nuray Chemical Private Limited (“Nuray”), which manufactures and supplies API to Novitium. As of September 30, 2022, Esjay no longer provided research and development and facilities consulting services to Novitium or ANI. Mr. Gassert holds a minority interest in Scitus. A summary of payments to related parties is presented below: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Scitus Pharma Services $ 1,322 $ 515 $ 3,227 $ 1,865 SS Pharma LLC 2,480 843 6,059 2,488 Esjay Pharma LLC — — — 101 Nuray Chemical Private Limited — 10 — 878 $ 3,802 $ 1,368 $ 9,286 $ 5,332 As of September 30, 2023, the outstanding balances due to Scitus and SS Pharma were $0.4 million and $0.8 million , respectively. There was no outstanding balance due to Nuray or Esjay at September 30, 2023.

SEGMENT REPORTING

SEGMENT REPORTING	9 Months Ended
SEGMENT REPORTING	Sep. 30, 2023
Segment Reporting [Abstract]
SEGMENT REPORTING	SEGMENT REPORTING An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity’s chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. The Company is organized into two operating segments as follows: • Generics, Established Brands, and Other – Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other. • Rare Disease – Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel. The CODM evaluates the two operating segments based on revenues and earnings before interest, income taxes, depreciation, and amortization (“EBITDA”), exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses. The Company does not manage assets of the Company by operating segment and our CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment. Financial information by reportable segment is as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Net Revenues Generics, Established Brands, and Other $ 102,095 $ 71,219 $ 284,794 $ 198,057 Rare Disease 29,734 12,602 70,368 24,096 Total net revenues $ 131,829 $ 83,821 $ 355,162 $ 222,153 Segment earnings (loss) before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to income (loss) before income taxes Generics, Established Brands, and Other $ 41,234 $ 22,099 $ 120,070 $ 52,103 Rare Disease 4,044 (2,382) 6,937 (19,493) Depreciation and amortization (15,207) (14,167) (44,597) (42,488) Corporate and other unallocated expenses (1) (12,123) (10,545) (42,165) (27,225) Total operating income (loss) 17,948 (4,995) 40,245 (37,103) Interest expense, net (6,398) (7,264) (21,194) (20,546) Other (expense) income, net (39) 37 (126) 712 Income (Loss) Before Income Tax (Expense) Benefit $ 11,511 $ (12,222) $ 18,925 $ (56,937) ______________________________________________ (1) Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations. Geographic Information Our operations are currently located in the United States and India. We have ceased operations at our Oakville, Ontario, Canada location as of March 31, 2023. The majority of the assets of the Company are located in the United States. The following table depicts the Company’s revenue by geographic operations during the following periods: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, Location of Operations 2023 2022 2023 2022 United States $ 131,829 $ 82,851 $ 354,597 $ 219,422 Canada — 970 565 2,731 Total Revenue $ 131,829 $ 83,821 $ 355,162 $ 222,153 The following table depicts the Company’s property, plant and equipment, net according to geographic location as of: (in thousands) September 30, 2023 December 31, 2022 United States $ 42,851 $ 40,343 Canada (1) — 1,856 India 1,338 1,047 Total property and equipment, net $ 44,189 $ 43,246 ______________________________________________ (1) Amounts as of September 30, 2023 and December 31, 2022 exclude the land and building at our Canada facility, which are classified as held for sale as of September 30, 2023 and December 31, 2022. These assets have a carrying value of approximately $8.0 million.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENT On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement with Mastercom Inc. ("Buyer") for the purchase and sale of the Oakville, Ontario manufacturing facility (the "Property") at a total purchase price of $17,850,000 Canadian dollars, or approximately $13,000,000 US Dollars based on the current exchange rate, subject to certain market adjustments. Under the terms and conditions of the purchase and sale agreement, Buyer paid a deposit upon signing of the Agreement of $500,000 Canadian dollars, or approximately $365,000 US Dollars based on the current exchange rate, and Buyer’s obligations under the agreement are subject to a twenty (20) business day due diligence period (the "Initial Due Diligence Period") that can be extended for an additional twenty (20) business days if an independent assessor recommends conducting a phase II environmental assessment (the “Due Diligence Condition”). In addition, Buyer’s obligations under the Agreement are subject to Buyer’s obtaining financing on terms satisfactory to Buyer prior to expiration of the Initial Due Diligence Period (the “Financing Condition”). Upon waiver or satisfaction of the Due Diligence Condition, Buyer is required to pay an additional deposit of $750,000 Canadian dollars, or approximately $550,000 US Dollars based on the current exchange rate, with the remaining balance of the purchase price (minus the deposited amounts) to be paid upon closing of the transaction. The closing of the transaction is subject to customary termination conditions, including the Buyer’s right to terminate the agreement if the Property is materially damaged prior to the closing. If the transaction does not close as a result of the Due Diligence Condition or the Financing Condition or as a result of ANI’s default under the agreement, the deposited amounts will be returned to the Buyer in full. ANI will retain the deposited amounts if the transaction does not close as a result of the Buyer’s default under the agreement.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net Income (Loss)	$ 9,940	$ (8,600)	$ 17,624	$ (43,653)

Insider Trading Arrangements

Insider Trading Arrangements - Meredith Cook [Member]	3 Months Ended	9 Months Ended
Insider Trading Arrangements - Meredith Cook [Member]	Sep. 30, 2023 shares	Sep. 30, 2023 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act.On August 11, 2023, Meredith Cook, Senior Vice President, General Counsel and Corporate Secretary of the Company, adopted a Rule 10b5-1 trading plan for the period commencing three months from such date and ending on December 31, 2024 for sale of up to 3,077 shares of common stock of the Company.
Name	Meredith Cook
Title	Senior Vice President, General Counsel and Corporate Secretary of the Company
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	August 11, 2023
Arrangement Duration	386 days
Aggregate Available	3,077	3,077

BUSINESS, PRESENTATION, AND R_2

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly the Company's financial position, results of operations, comprehensive income (loss), and cash flows. The consolidated balance sheet at December 31, 2022 has been derived from audited financial statements as of that date. The unaudited interim condensed consolidated statements of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to instructions, rules, and regulations prescribed by the U.S. Securities and Exchange Commission (the “SEC”). Therefore, these unaudited interim condensed consolidated financial statements should be read in conjunction with the Company's audited financial statements and notes thereto previously distributed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Form 10-K”), as filed with the SEC.
Principles of Consolidation	Principles of Consolidation The unaudited interim condensed consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.
Foreign Currency	Foreign Currency The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. We currently have a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the three and nine months ended September 30, 2023 and 2022. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar. The Company’s asset and liability accounts are translated using the current exchange rate as of the balance sheet date. Shareholders’ equity accounts are translated using historical rates at the balance sheet date. Net revenues and expense accounts are translated using a weighted average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company’s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders’ equity within accumulated other comprehensive income, net of tax.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the condensed consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, income tax provision or benefit, deferred taxes and valuation allowance, stock-based compensation, revenue recognition, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.
Restructuring Activities	Restructuring Activities The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in our consolidated statements of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recent Accounting Pronouncements Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and are adopted by the Company as of the specified effective date. The Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Recent Accounting Pronouncements Adopted In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting . This ASU provides optional expedients and exceptions, that may be elected over time as reference rate reform activities occur, for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance in this ASU was extended in December 2022 when the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848 , extending the sunset date under Topic 848 to December 31, 2024 to align the temporary accounting relief guidance with the expected LIBOR cessation. In August 2023, the Company completed the transition of its debt and derivative instruments from LIBOR to Adjusted Term Secured Overnight Financing Rate ("SOFR") and applied the optional expedients in ASC 848 related to contract modifications and changing critical terms of the Company’s hedging relationships. Application of these expedients allowed the Company to preserve presentation of derivatives as qualifying cash flow hedges and to account for the debt modification as a continuation of the existing contract. The adoption of this guidance did not have a material impact on the consolidated financial statements.

REVENUE RECOGNITION AND RELAT_2

REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)	9 Months Ended
REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)	Sep. 30, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue and revenue recognized	All revenue recognized in the accompanying unaudited interim condensed consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue: Three Months Ended Nine Months Ended Products and Services September 30, September 30, September 30, September 30, (in thousands) Sales of generic pharmaceutical products $ 70,593 $ 53,136 $ 197,623 $ 152,106 Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services 31,502 18,083 87,171 45,951 Sales of rare disease pharmaceutical products 29,734 12,602 70,368 24,096 Total net revenues $ 131,829 $ 83,821 $ 355,162 $ 222,153 Three Months Ended Nine Months Ended Timing of Revenue Recognition September 30, September 30, September 30, September 30, (in thousands) Performance obligations transferred at a point in time $ 131,829 $ 82,318 $ 354,787 $ 219,553 Performance obligations transferred over time — 1,503 375 2,600 Total $ 131,829 $ 83,821 $ 355,162 $ 222,153
Schedule of accruals and allowances	The following table summarizes activity in the condensed consolidated balance sheets for accruals and allowances for the nine months ended September 30, 2023 and 2022, respectively: Accruals for Chargebacks, Returns, and Other Allowances (in thousands) Chargebacks Government Returns Administrative Prompt Balance at December 31, 2021 $ 94,066 $ 5,492 $ 35,831 $ 13,100 $ 4,642 Accruals/Adjustments 480,626 14,104 18,751 30,475 15,746 Credits Taken Against Reserve (480,203) (10,851) (20,598) (28,766) (15,751) Balance at September 30, 2022 (1) $ 94,489 $ 8,745 $ 33,984 $ 14,809 $ 4,637 Balance at December 31, 2022 $ 148,562 $ 10,872 $ 33,399 $ 9,442 $ 6,488 Accruals/Adjustments 437,671 16,998 13,048 40,815 17,024 Credits Taken Against Reserve (501,841) (16,947) (15,009) (39,316) (18,366) Balance at September 30, 2023 (1) $ 84,392 $ 10,923 $ 31,438 $ 10,941 $ 5,146 ______________________________________________
Schedule of customer concentration	The three customers represent the total percentage of net revenues as follows: Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, Customer 1 35 % 23 % 33 % 26 % Customer 2 12 % 17 % 13 % 18 % Customer 3 12 % 16 % 13 % 15 % Customer 4 13 % 7 % 10 % 5 %

INDEBTEDNESS (Tables)

INDEBTEDNESS (Tables)	9 Months Ended
INDEBTEDNESS (Tables)	Sep. 30, 2023
Debt Disclosure [Abstract]
Schedule of carrying value of the current and non-current components of the term loan	The carrying value of the current and non-current components of the Term Facility as of September 30, 2023 and December 31, 2022 are: Current (in thousands) September 30, December 31, Current borrowing on debt $ 3,000 $ 3,000 Deferred financing costs (2,150) (2,150) Current debt, net of deferred financing costs $ 850 $ 850 Non-Current (in thousands) September 30, December 31, Non-current borrowing on debt $ 291,750 $ 294,000 Deferred financing costs (6,718) (8,331) Non-current debt, net of deferred financing costs and current component $ 285,032 $ 285,669
Schedule of contractual maturity of term loan and DDTL	The contractual maturity of the Term Facility is as follows for the period ending: (in thousands) Term Facility 2023 (remainder of the year) $ 750 2024 3,000 2025 3,000 2026 3,000 2027 285,000 Total $ 294,750
Schedule of components of total interest expense related to the notes and term loan	The following table sets forth the components of total interest expense related to the Term Facility during the three and nine months ended September 30, 2023 and 2022, as recognized in the accompanying unaudited interim condensed consolidated statements of operations for the three and nine months ended September 30, 2023 and 2022: Three Months Ended Nine Months Ended (in thousands) September 30, September 30, September 30, September 30, Contractual coupon $ 7,864 $ 6,834 $ 22,834 $ 19,014 Amortization of finance fees 591 592 1,773 1,773 Capitalized interest (142) (31) (440) (80) $ 8,313 $ 7,395 $ 24,167 $ 20,707

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
EARNINGS (LOSS) PER SHARE (Tables)	Sep. 30, 2023
Earnings Per Share [Abstract]
Schedule of earnings per share, basic and diluted	Earnings (loss) per share for the three and nine months ended September 30, 2023 and 2022 are calculated for basic and diluted earnings (loss) per share as follows: Basic Diluted Basic Diluted (in thousands, except per share amounts) Three Months Ended September 30, Three Months Ended September 30, Nine Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 2023 2022 2023 2022 Net income (loss) available to common shareholders $ 9,534 $ (9,006) $ 9,534 $ (9,006) $ 16,405 $ (44,871) $ 16,405 $ (44,871) Earnings allocated to participating securities (891) — (881) — (1,629) — (1,615) — Net income (loss) available to common shareholders $ 8,643 $ (9,006) $ 8,653 $ (9,006) $ 14,776 $ (44,871) $ 14,790 $ (44,871) Basic Weighted-Average Shares Outstanding 18,883 16,303 18,883 16,303 17,663 16,238 17,663 16,238 Dilutive effect of common stock options, ESPP, and performance stock units 242 — 160 — Diluted Weighted-Average Shares Outstanding 19,125 16,303 17,823 16,238 Income (loss) per share $ 0.46 $ (0.55) $ 0.45 $ (0.55) $ 0.84 $ (2.76) $ 0.83 $ (2.76)

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
INVENTORIES (Tables)	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consist of the following as of: (in thousands) September 30, 2023 December 31, 2022 Raw materials $ 58,748 $ 67,726 Packaging materials 8,870 7,720 Work-in-progress 3,577 1,889 Finished goods 35,395 28,020 Inventories $ 106,590 $ 105,355

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	9 Months Ended
GOODWILL AND INTANGIBLE ASSETS (Tables)	Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of components of intangible assets	The components of definite-lived intangible assets and indefinite-lived intangible assets, other than goodwill, are as follows: September 30, 2023 December 31, 2022 Remaining Weighted Average (in thousands) Gross Carrying Accumulated Gross Carrying Accumulated Definite-Lived Intangible Assets: Acquired ANDAs intangible assets $ 209,780 $ (94,139) $ 195,862 $ (75,606) 5.4 years NDAs and product rights 242,372 (179,193) 242,372 (162,188) 3.2 years Marketing and distribution rights 17,157 (14,031) 17,157 (13,309) 3.3 years Non-compete agreement 624 (624) 624 (602) — years Customer relationships 24,900 (6,818) 24,900 (4,150) 5.1 years Total Definite-Lived Intangible Assets 494,833 (294,805) 480,915 (255,855) 4.6 years Indefinite-Lived Intangible Assets: In process research and development 19,800 — 26,575 — Indefinite Total Intangible Assets, net $ 514,633 $ (294,805) $ 507,490 $ (255,855)
Schedule of expected future amortization expense for definite-lived intangible assets	Expected future amortization expense for definite-lived intangible assets is as follows: (in thousands) 2023 (remainder of the year) $ 13,319 2024 49,554 2025 46,319 2026 33,001 2027 24,089 2028 and thereafter 33,746 Total $ 200,028

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
STOCK-BASED COMPENSATION (Tables)	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of allocated expense	The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in our accompanying unaudited interim condensed consolidated statements of operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of sales $ 16 $ 11 $ 46 $ 40 Research and development 14 10 33 31 Selling, general, and administrative 109 82 251 142 $ 139 $ 103 $ 330 $ 213 The following table summarizes stock-based compensation expense incurred under the 2022 Plan and Inducement Grants included in the accompanying unaudited interim condensed consolidated statements of operations: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Cost of sales $ 166 $ 134 $ 475 $ 393 Research and development 225 186 638 531 Selling, general, and administrative 4,914 3,447 13,588 9,725 $ 5,305 $ 3,767 $ 14,701 $ 10,649
Summary of stock option and restricted stock activity	A summary of stock option, RSA, and PSU activity under the 2022 Plan and Inducement Grants during the nine months ended September 30, 2023 is presented below: (in thousands) Options Inducement Grants PSUs RSAs Outstanding at December 31, 2021 747 241 — 707 Granted 36 — — 723 Options Exercised/RSAs Vested (16) — — (234) (1) Forfeited (58) — — (46) Expired — — — — Outstanding at September 30, 2022 709 241 — 1,150 Outstanding at December 31, 2022 907 241 — 1,141 Granted 3 — 85 648 Options Exercised/RSAs Vested (151) — — (369) (2) Forfeited (28) — (1) (76) Expired — — — — Outstanding at September 30, 2023 731 241 84 1,344 ______________________________________________ (1) Includes 63 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $1.9 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets. (2) Includes 111 thousand shares purchased from employees to cover employee income taxes related to income earned upon vesting of restricted stock. The shares purchased are held in treasury and the $4.8 million total purchase price for the shares is included in Treasury stock in our accompanying unaudited interim condensed consolidated balance sheets.

FAIR VALUE DISCLOSURES (Tables)

FAIR VALUE DISCLOSURES (Tables)	9 Months Ended
FAIR VALUE DISCLOSURES (Tables)	Sep. 30, 2023
Fair Value Disclosures [Abstract]
Schedule of recurring Level 3 fair value measurements of contingent consideration	The discounted cash flow method used to value this contingent consideration includes inputs which are classified as Level 3 inputs, as the inputs are not based on readily available market data. The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Payment Type Valuation Technique Unobservable Input Assumptions Profit-based milestone payments Probability-weighted discounted cash flow Discount rate 13.0% Projected fiscal year of payment 2025-2035 Product development-based milestone payments Probability-weighted discounted cash flow Discount rate 9.0% - 13.0% Probability of payment 100.0% Projected fiscal year of payment 2024
Schedule of changes in contingent consideration	The following table presents the changes in contingent consideration balances classified as Level 3 for the three and nine months ended September 30, 2023 and 2022: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Beginning balance $ 37,054 $ 30,958 $ 35,058 $ 31,000 Measurement period adjustment — — — 300 Change in fair value (2,555) 2,476 (559) 2,134 Ending balance $ 34,499 $ 33,434 $ 34,499 $ 33,434
Schedule of financial assets and liabilities accounted for at fair value on a recurring basis	The following table presents our financial assets and liabilities accounted for at fair value on a recurring basis as of September 30, 2023 and December 31, 2022, by level within the fair value hierarchy: (in thousands) Fair Value at Level 1 Level 2 Level 3 Assets Interest rate swap $ 10,014 $ — $ 10,014 $ — Liabilities Contingent consideration $ 34,499 $ — $ — $ 34,499 Description Fair Value at Level 1 Level 2 Level 3 Assets Interest rate swap $ 8,759 $ — $ 8,759 $ — Liabilities Contingent consideration $ 35,058 $ — $ — $ 35,058

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	9 Months Ended
RELATED PARTY TRANSACTIONS (Tables)	Sep. 30, 2023
Related Party Transactions [Abstract]
Schedule of related party transactions	A summary of payments to related parties is presented below: Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 2023 2022 Scitus Pharma Services $ 1,322 $ 515 $ 3,227 $ 1,865 SS Pharma LLC 2,480 843 6,059 2,488 Esjay Pharma LLC — — — 101 Nuray Chemical Private Limited — 10 — 878 $ 3,802 $ 1,368 $ 9,286 $ 5,332

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	9 Months Ended
SEGMENT REPORTING (Tables)	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of financial information by reportable segments	Financial information by reportable segment is as follows: Three Months Ended September 30, Nine Months Ended September 30, (in thousands) 2023 2022 2023 2022 Net Revenues Generics, Established Brands, and Other $ 102,095 $ 71,219 $ 284,794 $ 198,057 Rare Disease 29,734 12,602 70,368 24,096 Total net revenues $ 131,829 $ 83,821 $ 355,162 $ 222,153 Segment earnings (loss) before interest, taxes, depreciation and amortization (“EBITDA”) and reconciliation to income (loss) before income taxes Generics, Established Brands, and Other $ 41,234 $ 22,099 $ 120,070 $ 52,103 Rare Disease 4,044 (2,382) 6,937 (19,493) Depreciation and amortization (15,207) (14,167) (44,597) (42,488) Corporate and other unallocated expenses (1) (12,123) (10,545) (42,165) (27,225) Total operating income (loss) 17,948 (4,995) 40,245 (37,103) Interest expense, net (6,398) (7,264) (21,194) (20,546) Other (expense) income, net (39) 37 (126) 712 Income (Loss) Before Income Tax (Expense) Benefit $ 11,511 $ (12,222) $ 18,925 $ (56,937) ______________________________________________ (1) Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our unaudited interim consolidated statement of operations.
Schedule of revenue by geographic operations	The following table depicts the Company’s revenue by geographic operations during the following periods: (in thousands) Three Months Ended September 30, Nine Months Ended September 30, Location of Operations 2023 2022 2023 2022 United States $ 131,829 $ 82,851 $ 354,597 $ 219,422 Canada — 970 565 2,731 Total Revenue $ 131,829 $ 83,821 $ 355,162 $ 222,153
Schedule of property, plant and equipment, net by geographic location	(in thousands) September 30, 2023 December 31, 2022 United States $ 42,851 $ 40,343 Canada (1) — 1,856 India 1,338 1,047 Total property and equipment, net $ 44,189 $ 43,246 ______________________________________________ (1) Amounts as of September 30, 2023 and December 31, 2022 exclude the land and building at our Canada facility, which are classified as held for sale as of September 30, 2023 and December 31, 2022. These assets have a carrying value of approximately $8.0 million.

BUSINESS, PRESENTATION, AND R_3

BUSINESS, PRESENTATION, AND RECENT ACCOUNTING PRONOUNCEMENTS (Details) - Common Stock - Public Offering $ in Millions	1 Months Ended
	May 31, 2023 USD ($) shares
Debt Instrument [Line Items]
Issuance of common stock (in shares) \| shares	2,183,545
Net proceeds after issuance costs \| $	$ 80.6

REVENUE RECOGNITION AND RELAT_3

REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total net revenues	$ 131,829	$ 83,821	$ 355,162	$ 222,153
Sales of generic pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	70,593	53,136	197,623	152,106
Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services
Disaggregation of Revenue [Line Items]
Total net revenues	31,502	18,083	87,171	45,951
Sales of rare disease pharmaceutical products
Disaggregation of Revenue [Line Items]
Total net revenues	$ 29,734	$ 12,602	$ 70,368	$ 24,096

REVENUE RECOGNITION AND RELAT_4

REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation of Revenue [Line Items]
Total net revenues	$ 131,829	$ 83,821	$ 355,162	$ 222,153
Performance obligations satisfied in prior periods			8,500	2,600
Sales of contract manufacture products
Disaggregation of Revenue [Line Items]
Remaining performance obligations	4,000		4,000
Performance obligations transferred at a point in time
Disaggregation of Revenue [Line Items]
Total net revenues	131,829	82,318	354,787	219,553
Performance obligations transferred over time
Disaggregation of Revenue [Line Items]
Total net revenues	$ 0	1,503	$ 375	2,600
Maximum
Disaggregation of Revenue [Line Items]
Revenue recognized		$ 100		$ 100

REVENUE RECOGNITION AND RELAT_5

REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	$ 161,052
Ending balance	97,774
Chargebacks
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	148,562	$ 94,066
Accruals/Adjustments	437,671	480,626
Credits Taken Against Reserve	(501,841)	(480,203)
Ending balance	84,392	94,489
Government Rebates
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	10,872	5,492
Accruals/Adjustments	16,998	14,104
Credits Taken Against Reserve	(16,947)	(10,851)
Ending balance	10,923	8,745
Returns
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	33,399	35,831
Accruals/Adjustments	13,048	18,751
Credits Taken Against Reserve	(15,009)	(20,598)
Ending balance	31,438	33,984
Administrative Fees and Other Rebates
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	9,442	13,100
Accruals/Adjustments	40,815	30,475
Credits Taken Against Reserve	(39,316)	(28,766)
Ending balance	10,941	14,809
Prompt Payment Discounts
Accruals for Chargebacks, Returns, and Other Allowances
Beginning balance	6,488	4,642
Accruals/Adjustments	17,024	15,746
Credits Taken Against Reserve	(18,366)	(15,751)
Ending balance	$ 5,146	$ 4,637

REVENUE RECOGNITION AND RELAT_6

REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details) - Customer Concentration Risk	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Accounts Receivable \| Four Customers
Concentration Risk [Line Items]
Concentration risk, percentage			85%
Revenue from Contract with Customer Benchmark \| Customer 1
Concentration Risk [Line Items]
Concentration risk, percentage	35%	23%	33%	26%
Revenue from Contract with Customer Benchmark \| Customer 2
Concentration Risk [Line Items]
Concentration risk, percentage	12%	17%	13%	18%
Revenue from Contract with Customer Benchmark \| Customer 3
Concentration Risk [Line Items]
Concentration risk, percentage	12%	16%	13%	15%
Revenue from Contract with Customer Benchmark \| Customer 4
Concentration Risk [Line Items]
Concentration risk, percentage	13%	7%	10%	5%

RESTRUCTURING (Details)

RESTRUCTURING (Details) - USD ($)	3 Months Ended		9 Months Ended
RESTRUCTURING (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Restructuring
Restructuring activity expense	$ 0	$ 1,541,000	$ 1,132,000	$ 4,111,000
Assets held for sale	8,020,000		8,020,000		$ 8,020,000
Oakville, Ontario, Canada
Restructuring
Restructuring activity expense	0		1,100,000
Restructuring accrual	100,000		100,000
Assets held for sale	$ 8,000,000		8,000,000
Oakville, Ontario, Canada \| Employee Severance
Restructuring
Restructuring activity expense			200,000
Oakville, Ontario, Canada \| Facility Closing
Restructuring
Restructuring activity expense			700,000
Oakville, Ontario, Canada \| Other Restructuring
Restructuring
Restructuring activity expense			$ 200,000

INDEBTEDNESS - Credit facility

INDEBTEDNESS - Credit facility (Details) - Credit Facility - 2021 - USD ($) $ in Millions		1 Months Ended
	Nov. 19, 2021	Jul. 31, 2023	Sep. 30, 2023
Debt Instrument [Line Items]
Payments of debt issuance costs	$ 14
Term Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 300
Debt effective interest rate (as a percent)			11.45%
Principal amount			$ 294.8
Term Facility \| Base Rate
Debt Instrument [Line Items]
Basis spread (as a percent)	5%
Term Facility \| LIBOR
Debt Instrument [Line Items]
Basis spread (as a percent)	6%
Revolving Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 40
Remaining borrowing capacity			40
Commitment fee (as a percent)	0.50%
Deferred debt issuance costs			0.7
Debt issuance costs, noncurrent			0.5
Debt issuance costs, current			$ 0.2
Revolving Facility \| One Month Duration
Debt Instrument [Line Items]
Basis spread (as a percent)		0.11448%
Revolving Facility \| Three Month Duration
Debt Instrument [Line Items]
Basis spread (as a percent)		0.26161%
Revolving Facility \| Six Month Duration
Debt Instrument [Line Items]
Basis spread (as a percent)		0.42826%
Revolving Facility \| Base Rate
Debt Instrument [Line Items]
Basis spread (as a percent)	3.75%
Revolving Facility \| LIBOR
Debt Instrument [Line Items]
Basis spread (as a percent)	4.75%

INDEBTEDNESS - Facility compone

INDEBTEDNESS - Facility components (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Current debt, net of deferred financing costs	$ 850	$ 850
Non-current debt, net of deferred financing costs and current component	285,032	285,669
Term Loan and DDTL
Debt Instrument [Line Items]
Current borrowing on debt	3,000	3,000
Deferred financing costs	(2,150)	(2,150)
Current debt, net of deferred financing costs	850	850
Non-current borrowing on debt	291,750	294,000
Deferred financing costs	(6,718)	(8,331)
Non-current debt, net of deferred financing costs and current component	$ 285,032	$ 285,669

INDEBTEDNESS - Maturity of cred

INDEBTEDNESS - Maturity of credit facility (Details) - Term Facility $ in Thousands	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
2023 (remainder of the year)	$ 750
2024	3,000
2025	3,000
2026	3,000
2027	285,000
Total	$ 294,750

INDEBTEDNESS - Interest (Detail

INDEBTEDNESS - Interest (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INDEBTEDNESS - Interest (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Debt Disclosure [Abstract]
Contractual coupon	$ 7,864	$ 6,834	$ 22,834	$ 19,014
Amortization of finance fees	591	592	1,773	1,773
Capitalized interest	(142)	(31)	(440)	(80)
Interest Expense, Debt	$ 8,313	$ 7,395	$ 24,167	$ 20,707

DERIVATIVE FINANCIAL INSTRUME_2

DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Nov. 21, 2021
Derivative [Line Items]
Fair value interest rate derivative assets	$ 10,014		$ 10,014		$ 8,759
Accumulated other comprehensive income, net of tax	14,076		14,076		$ 12,168
Derivative unrealized gain recorded in OCI	388	$ 4,609	1,857	$ 13,094
Interest Rate Swap
Derivative [Line Items]
Derivative liability, notional amount	139,400		139,400			$ 168,600
Debt effective interest rate (as a percent)						2.26%
Decrease in notional amount			4,000
Fair value interest rate derivative assets	10,000		10,000
Accumulated other comprehensive income, net of tax	14,100		14,100
Derivative unrealized gain	500		300
Derivative unrealized gain recorded in OCI	400		1,900
Interest expense	700		1,800
Reclassifications out of accumulated other comprehensive income (loss)	$ 700	$ 700
Terminated and de-designated cash flow hedges income (expense)			$ 2,100	$ 2,100

EARNINGS (LOSS) PER SHARE (Deta

EARNINGS (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Basic
Net income (loss) available to common shareholders, Basic	$ 9,534	$ (9,006)	$ 16,405	$ (44,871)
Earnings allocated to participating securities, Basic	(891)	0	(1,629)	0
Net income (loss) available to common shareholders, Basic	8,643	(9,006)	14,776	(44,871)
Diluted
Net income (loss) available to common shareholders, Diluted	9,534	(9,006)	16,405	(44,871)
Earnings allocated to participating securities, Diluted	(881)	0	(1,615)	0
Net income (loss) available to common shareholders, Diluted	$ 8,653	$ (9,006)	$ 14,790	$ (44,871)
Basic
Basic Weighted-Average Shares Outstanding (in shares)	18,883	16,303	17,663	16,238
Diluted
Dilutive effect of common stock options, ESPP, and performance stock units (in shares)	242	0	160	0
Diluted Weighted-Average Shares Outstanding (in shares)	19,125	16,303	17,823	16,238
Basic
Income (loss) per share, Basic (in dollars per share)	$ 0.46	$ (0.55)	$ 0.84	$ (2.76)
Diluted
Income (loss) per share, Diluted (in dollars per share)	$ 0.45	$ (0.55)	$ 0.83	$ (2.76)
Anti-dilutive shares diluted earnings (loss) per share (in shares)	2,100	2,700	2,400	2,700

INVENTORIES - Schedule of inven

INVENTORIES - Schedule of inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 58,748	$ 67,726
Packaging materials	8,870	7,720
Work-in-progress	3,577	1,889
Finished goods	35,395	28,020
Inventories	$ 106,590	$ 105,355

INVENTORIES - Concentration (De

INVENTORIES - Concentration (Details)	9 Months Ended
INVENTORIES - Concentration (Details)	Sep. 30, 2022
Supplier Concentration Risk \| Cost of Goods and Service Benchmark \| One supplier
Inventory [Line Items]
Concentration risk, percentage	13%

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2023 segment	Dec. 31, 2021 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2013 USD ($)
Goodwill [Line Items]
Number of operating segments \| segment	2
Number of reporting units \| segment	2
BioSante Pharmaceuticals
Goodwill [Line Items]
Acquisition of goodwill				$ 1.8
WellSpring
Goodwill [Line Items]
Acquisition of goodwill			$ 1.7
Novitium
Goodwill [Line Items]
Acquisition of goodwill		$ 24.6

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Components (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 494,833		$ 494,833		$ 480,915
Accumulated Amortization	$ (294,805)		$ (294,805)		(255,855)
Remaining Weighted Average Amortization Period	4 years 7 months 6 days		4 years 7 months 6 days
Indefinite-Lived Intangible Assets:
Total Intangible Assets, Gross	$ 514,633		$ 514,633		507,490
Amortization of intangible assets	13,300	$ 12,500	39,000	$ 36,900
Intangible asset impairment charge	$ 0	0	$ 0	$ 112
Minimum
Indefinite-Lived Intangible Assets:
Remaining estimated useful lives	7 years		7 years
Maximum
Indefinite-Lived Intangible Assets:
Remaining estimated useful lives	10 years		10 years
In process research and development
Indefinite-Lived Intangible Assets:
Gross Carrying Amount	$ 19,800		$ 19,800		26,575
Acquired ANDAs intangible assets
Definite-Lived Intangible Assets:
Gross Carrying Amount	209,780		209,780		195,862
Accumulated Amortization	$ (94,139)		$ (94,139)		(75,606)
Remaining Weighted Average Amortization Period	5 years 4 months 24 days		5 years 4 months 24 days
Indefinite-Lived Intangible Assets:
Intangible assets acquired	$ 6,800
Capitalized intangible assets		$ 2,800
NDAs and product rights
Definite-Lived Intangible Assets:
Gross Carrying Amount	242,372		$ 242,372		242,372
Accumulated Amortization	$ (179,193)		$ (179,193)		(162,188)
Remaining Weighted Average Amortization Period	3 years 2 months 12 days		3 years 2 months 12 days
Marketing and distribution rights
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 17,157		$ 17,157		17,157
Accumulated Amortization	$ (14,031)		$ (14,031)		(13,309)
Remaining Weighted Average Amortization Period	3 years 3 months 18 days		3 years 3 months 18 days
Non-compete agreement
Definite-Lived Intangible Assets:
Gross Carrying Amount	$ 624		$ 624		624
Accumulated Amortization	(624)		(624)		(602)
Customer relationships
Definite-Lived Intangible Assets:
Gross Carrying Amount	24,900		24,900		24,900
Accumulated Amortization	$ (6,818)		$ (6,818)		$ (4,150)
Remaining Weighted Average Amortization Period	5 years 1 month 6 days		5 years 1 month 6 days

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2023 (remainder of the year)	$ 13,319
2024	49,554
2025	46,319
2026	33,001
2027	24,089
2028 and thereafter	33,746
Total	$ 200,028

MEZZANINE AND STOCKHOLDERS' E_2

MEZZANINE AND STOCKHOLDERS' EQUITY (Details) $ / shares in Units, $ in Millions	Nov. 19, 2021 USD ($) tradingDay $ / shares shares	Mar. 08, 2021 USD ($) $ / shares shares	Sep. 30, 2023 vote $ / shares shares	Jun. 30, 2023 shares	Dec. 31, 2022 $ / shares shares	Sep. 30, 2022 shares	Jun. 30, 2022 shares	Dec. 31, 2021 shares
Temporary Equity [Line Items]
Preferred Stock, shares authorized			1,666,667		1,666,667
Preferred Stock, par value (in dollars per share) \| $ / shares			$ 0.0001		$ 0.0001
Common Stock
Temporary Equity [Line Items]
Common Stock, shares authorized			33,333,334		33,333,334
Common Stock, par value (in dollars per share) \| $ / shares			$ 0.0001		$ 0.0001
Common Stock, shares issued			20,653,794		17,643,497
Common Stock, shares outstanding			20,394,244		17,494,466
PIPE Shares \| Convertible Preferred Stock
Temporary Equity [Line Items]
Temporary stock issued (in shares)	25,000	25,000
Temporary stock issued (in dollars per share) \| $ / shares	$ 1,000	$ 1,000
Temporary stock issued, value \| $	$ 25	$ 25
Shares accrue dividends rate	6.50%
Shares conversion price (in dollars per share) \| $ / shares	$ 41.47
Minimum conversion period	2 years
Threshold number of trading days \| tradingDay	20
Number of consecutive trading days \| tradingDay	30
Maximum percentage of conversion price	1.70%
Convertible, shares issuable			602,901
Class C Special Stock
Temporary Equity [Line Items]
Common Stock, shares authorized			800,000
Common Stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Common Stock, shares issued			11,000
Common Stock, shares outstanding			11,000
Vote per share \| vote			1
Exchange per share			1
Common Stock, conversion price (in dollars per share) \| $ / shares			$ 90
Common Stock
Temporary Equity [Line Items]
Common Stock, shares authorized			33,300,000
Common Stock, par value (in dollars per share) \| $ / shares			$ 0.0001
Common Stock, shares outstanding			20,654,000	20,536,000	17,644,000	17,614,000	17,566,000	16,913,000

STOCK-BASED COMPENSATION - Expe

STOCK-BASED COMPENSATION - Expense (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	May 23, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
2016 Employee Stock Purchase Plan
Share-based Compensation
Stock-based compensation shares available		100,000		100,000
Discount from market price (as a percent)				15%
Allocated share-based compensation expense		$ 139	$ 103	$ 330	$ 213
2016 Employee Stock Purchase Plan \| Cost of sales
Share-based Compensation
Allocated share-based compensation expense		16	11	46	40
2016 Employee Stock Purchase Plan \| Research and development
Share-based Compensation
Allocated share-based compensation expense		14	10	33	31
2016 Employee Stock Purchase Plan \| Selling, general, and administrative
Share-based Compensation
Allocated share-based compensation expense		$ 109	82	$ 251	142
2022 Plan
Share-based Compensation
Stock-based compensation shares available		1,100,000		1,100,000
Allocated share-based compensation expense		$ 5,305	3,767	$ 14,701	10,649
Stock-based compensation additional shares authorized	750,000
2022 Plan \| Cost of sales
Share-based Compensation
Allocated share-based compensation expense		166	134	475	393
2022 Plan \| Research and development
Share-based Compensation
Allocated share-based compensation expense		225	186	638	531
2022 Plan \| Selling, general, and administrative
Share-based Compensation
Allocated share-based compensation expense		$ 4,914	$ 3,447	$ 13,588	$ 9,725

STOCK-BASED COMPENSATION - Info

STOCK-BASED COMPENSATION - Information (Details)	9 Months Ended
STOCK-BASED COMPENSATION - Information (Details)	Sep. 30, 2023 installment
Options
Share-based Compensation
Number of annual installments	4
Options \| Employees and Consultants
Share-based Compensation
Vesting period	4 years
Award expiration period	10 years
Options \| Non Employee Director
Share-based Compensation
Award expiration period	10 years
Options \| Non Employee Director \| Minimum
Share-based Compensation
Vesting period	1 year
Options \| Non Employee Director \| Maximum
Share-based Compensation
Vesting period	4 years
RSAs \| Employees and Consultants
Share-based Compensation
Vesting period	4 years
RSAs \| Non Employee Director
Share-based Compensation
Vesting period	1 year

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details)	9 Months Ended
STOCK-BASED COMPENSATION - Narrative (Details)	Sep. 30, 2023 $ / shares shares
Performance-Based Restricted Stock Units
Share-based Compensation
Performance period	3 years
Percentage of awards	50%
Vesting period	3 years
Maximum potential to vest percentage	200%
Maximum potential to vest (in shares) \| shares	85,099
Grate date fair value (in dollars per share) \| $ / shares	$ 41.84
Estimate number of shares percentage	100%
Market Performance-Based Restricted Stock Units
Share-based Compensation
Percentage of awards	50%
Vesting period	3 years
Maximum potential to vest percentage	200%
Maximum potential to vest (in shares) \| shares	85,099
Grate date fair value (in dollars per share) \| $ / shares	$ 68.65
Estimate number of shares percentage	100%

STOCK-BASED COMPENSATION - Opti

STOCK-BASED COMPENSATION - Option activity (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Options
Option Shares
Outstanding at the beginning of the period (in shares)	907	747
Granted (in shares)	3	36
Exercised (in shares)	(151)	(16)
Forfeited (in shares)	(28)	(58)
Expired (in shares)	0	0
Outstanding at the end of the period (in shares)	731	709
Inducement Grants
Option Shares
Outstanding at the beginning of the period (in shares)	241	241
Granted (in shares)	0	0
Exercised (in shares)	0	0
Forfeited (in shares)	0	0
Expired (in shares)	0	0
Outstanding at the end of the period (in shares)	241	241

STOCK-BASED COMPENSATION - Non-

STOCK-BASED COMPENSATION - Non-option activity (Details) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Non-option Shares
Treasury stock value	$ 9,850		$ 5,094
PSUs
Non-option Shares
Outstanding at the beginning of the period (in shares)	0	0
Granted (in shares)	85	0
Exercised (in shares)	0	0
Forfeited (in shares)	(1)	0
Expired (in shares)	0	0
Outstanding at the end of the period (in shares)	84	0
RSAs
Non-option Shares
Outstanding at the beginning of the period (in shares)	1,141	707
Granted (in shares)	648	723
Exercised (in shares)	(369)	(234)
Forfeited (in shares)	(76)	(46)
Expired (in shares)	0	0
Outstanding at the end of the period (in shares)	1,344	1,150
Shares purchased to cover employee income taxes	111	63
Treasury stock value	$ 4,800	$ 1,900
Options
Non-option Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	0	0
Inducement Grants
Non-option Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period	0	0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Valuation allowance	$ 400		$ 400
Expense (benefit) for income taxes	$ (1,571)	$ 3,622	$ (1,301)	$ 13,284
Effective income tax rate (as a percent)	13.60%	29.60%	6.90%	23.30%
Pre-tax consolidated income (loss)	$ 11,511	$ (12,222)	$ 18,925	$ (56,937)

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands			1 Months Ended		2 Months Ended	3 Months Ended		9 Months Ended
COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Feb. 15, 2022 USD ($)	Jul. 08, 2021 plaintiff	Sep. 30, 2022 plaintiff	Aug. 31, 2022 plaintiff	Sep. 30, 2022 plaintiff	Sep. 30, 2023 USD ($) product	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) product	Sep. 30, 2022 USD ($)	Apr. 30, 2023
COMMITMENTS AND CONTINGENCIES
Lease term										5 years
Number of products marketed without approved NDAs or ANDAs \| product						3		3
Total net revenues \| $						$ 131,829	$ 83,821	$ 355,162	$ 222,153
Federal Court Personal Injury Litigation
COMMITMENTS AND CONTINGENCIES
Number of plaintiffs \| plaintiff		114
State Court Personal Injury Litigation \| Illinois
COMMITMENTS AND CONTINGENCIES
Number of plaintiffs \| plaintiff				6
State Court Personal Injury Litigation \| California
COMMITMENTS AND CONTINGENCIES
Number of plaintiffs \| plaintiff					7
State Court Personal Injury Litigation \| Pennsylvania
COMMITMENTS AND CONTINGENCIES
Number of plaintiffs \| plaintiff			2
Azurity Pharmaceuticals
COMMITMENTS AND CONTINGENCIES
Settlement amount awarded to other party \| $	$ 1,900
Royalties on future sales (as a percent)	20%
Unapproved Products
COMMITMENTS AND CONTINGENCIES
Total net revenues \| $						9,200	3,100	16,400	10,000
Unapproved Products \| Contract Customer
COMMITMENTS AND CONTINGENCIES
Total net revenues \| $						$ 100	$ 1,000	$ 1,100	$ 2,100

FAIR VALUE DISCLOSURES - Narrat

FAIR VALUE DISCLOSURES - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Interest rate swap	$ 10,014	$ 8,759
Achievement of milestones payment period	24 months
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Additional contingent consideration	$ 46,500

FAIR VALUE DISCLOSURES - Level

FAIR VALUE DISCLOSURES - Level 3 (Details) $ in Thousands	3 Months Ended		9 Months Ended
FAIR VALUE DISCLOSURES - Level 3 (Details) $ in Thousands	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Changes in contingent consideration
Level 3 liability, beginning balance	$ 37,054	$ 30,958	$ 35,058	$ 31,000
Measurement period adjustment	0	0	0	300
Change in fair value	$ (2,555)	$ 2,476	$ (559)	$ 2,134
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment	Contingent consideration fair value adjustment
Level 3 liability, ending balance	$ 34,499	$ 33,434	$ 34,499	$ 33,434
Discount rate \| Probability-weighted discounted cash flow \| Profit-based milestone payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable inputs	13		13
Discount rate \| Probability-weighted discounted cash flow \| Product development-based milestone payments \| Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable inputs	0.090		0.090
Discount rate \| Probability-weighted discounted cash flow \| Product development-based milestone payments \| Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable inputs	0.130		0.130
Probability of payment \| Probability-weighted discounted cash flow \| Product development-based milestone payments
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable inputs	100		100

FAIR VALUE DISCLOSURES - Hierar

FAIR VALUE DISCLOSURES - Hierarchy (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Interest rate swap	$ 10,014	$ 8,759
Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Interest rate swap	0	0
Level 2
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Interest rate swap	10,014	8,759
Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Interest rate swap	0	0
Novitium
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration	34,499	35,058
Novitium \| Level 1
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration	0	0
Novitium \| Level 2
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration	0	0
Novitium \| Level 3
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration	$ 34,499	$ 35,058

FAIR VALUE DISCLOSURES - Acquir

FAIR VALUE DISCLOSURES - Acquired (Details)		3 Months Ended			9 Months Ended
FAIR VALUE DISCLOSURES - Acquired (Details)	Aug. 14, 2023 USD ($) patent	Sep. 30, 2023 USD ($)	Jun. 30, 2023 USD ($) product	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Payment for acquired intangible assets					$ 7,143,000	$ 7,575,000
Intangible asset impairment charge		$ 0		$ 0	0	$ 112,000
Acquired ANDAs intangible assets
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Intangible assets acquired		6,800,000
Slayback Pharma LLC \| Acquired ANDAs intangible assets
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of acquired non-financial assets \| patent	1
Payment for acquired intangible assets	$ 3,000,000
Intangible assets acquired	$ 2,800,000
Useful life of intangible assets	7 years
Akorn Holding Company \| Acquired ANDAs intangible assets
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of acquired non-financial assets \| product			2
Intangible assets acquired			$ 4,300,000
Useful life of intangible assets			7 years
Number of acquired pipeline products \| product			1
Total asset purchase			$ 4,800,000
Number of commercial products \| product			2
Intangible asset impairment charge		$ 0			$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details)			3 Months Ended		9 Months Ended
RELATED PARTY TRANSACTIONS (Details)	Nov. 19, 2021 USD ($) $ / shares shares	Mar. 08, 2021 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) founder	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) founder	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Related Party Transaction [Line Items]
Number of employment agreements with executives and founders \| founder			2		2
Outstanding balances			$ 34,077,000		$ 34,077,000		$ 29,305,000
Convertible Preferred Stock \| PIPE Shares
Related Party Transaction [Line Items]
Temporary stock issued (in shares) \| shares	25,000	25,000
Temporary stock issued (in dollars per share) \| $ / shares	$ 1,000	$ 1,000
Temporary stock issued, value	$ 25,000,000	$ 25,000,000
Related Party
Related Party Transaction [Line Items]
Payments to related party			3,802,000	$ 1,368,000	9,286,000	$ 5,332,000
Related Party \| Scitus Pharma Services
Related Party Transaction [Line Items]
Payments to related party			1,322,000	515,000	3,227,000	1,865,000
Outstanding balances			400,000		400,000
Related Party \| SS Pharma LLC
Related Party Transaction [Line Items]
Payments to related party			2,480,000	843,000	6,059,000	2,488,000
Outstanding balances			800,000		800,000
Related Party \| Esjay Pharma LLC
Related Party Transaction [Line Items]
Payments to related party			0	0	0	101,000
Related Party \| Nuray Chemical Private Limited
Related Party Transaction [Line Items]
Payments to related party			0	$ 10,000	0	$ 878,000
Outstanding balances			$ 0		$ 0

SEGMENT REPORTING - Revenue (De

SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended		9 Months Ended
SEGMENT REPORTING - Revenue (Details) $ in Thousands	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) segment	Sep. 30, 2022 USD ($)
Segment reporting
Number of operating segments \| segment			2
Total net revenues	$ 131,829	$ 83,821	$ 355,162	$ 222,153
Depreciation and amortization	15,207	14,167	44,597	42,488
Corporate and other unallocated expenses	42,007	30,081	117,235	90,856
Operating Income (Loss)	17,948	(4,995)	40,245	(37,103)
Interest expense, net	(6,398)	(7,264)	(21,194)	(20,546)
Other (expense) income, net	(39)	37	(126)	712
Income (Loss) Before Income Tax (Expense) Benefit	11,511	(12,222)	18,925	(56,937)
Operating Segments \| Generics, Established Brands, and Other
Segment reporting
Total net revenues	102,095	71,219	284,794	198,057
EBITDA	41,234	22,099	120,070	52,103
Operating Segments \| Rare Disease
Segment reporting
Total net revenues	29,734	12,602	70,368	24,096
EBITDA	4,044	(2,382)	6,937	(19,493)
Corporate, Non-Segment
Segment reporting
Depreciation and amortization	(15,207)	(14,167)	(44,597)	(42,488)
Corporate and other unallocated expenses	(12,123)	(10,545)	(42,165)	(27,225)
Operating Income (Loss)	17,948	(4,995)	40,245	(37,103)
Interest expense, net	(6,398)	(7,264)	(21,194)	(20,546)
Other (expense) income, net	$ (39)	$ 37	$ (126)	$ 712

SEGMENT REPORTING - Geographic

SEGMENT REPORTING - Geographic (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Segment reporting
Total net revenues	$ 131,829	$ 83,821	$ 355,162	$ 222,153
Total property and equipment, net	44,189		44,189		$ 43,246
Assets held for sale	8,020		8,020		8,020
United States
Segment reporting
Total net revenues	131,829	82,851	354,597	219,422
Total property and equipment, net	42,851		42,851		40,343
Canada
Segment reporting
Total net revenues	0	$ 970	565	$ 2,731
Total property and equipment, net	0		0		1,856
Assets held for sale	8,000		8,000		8,000
India
Segment reporting
Total property and equipment, net	$ 1,338		$ 1,338		$ 1,047

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - 1 months ended Oct. 31, 2023 - Subsequent Event - Oakville, Ontario Former Manufacturing Facility - Disposal Group, Held-for-Sale, Not Discontinued Operations $ in Thousands, $ in Thousands	CAD ($)	USD ($)	USD ($)
Subsequent Event [Line Items]
Consideraiton	$ 17,850		$ 13,000
Deposit	$ 500	$ 365
Initial due diligence period	20 years	20 years
Initial due diligence period, extension	20 years	20 years
Deposit to be received upon due diligence condition	$ 750	$ 550